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 Ubiquitin carboxyl-terminal hydrolase 37, or UCH37, is a deubiquitinating 
enzyme associated with the 26S proteasome, the primary protein degradation 
machinery in eukaryotic cells. UCH37 is responsible for the disassembly of 
polymeric ubiquitin chains, or polyubiquitin, which have been ligated onto 
proteins in order to target them for degradation. The 26S utilizes two associated 
deubiquitinating enzymes, UCH37 and USP14, and one intrinsic, Rpn11, to 
remove polyubiquitin chains from substrate proteins as they are unfolded and 
translocated into the proteolytic core of the proteasome, where proteins are 
cleaved into small peptides and then released for recycling by the cell. UCH37 
associates with the proteasome via binding of its C-terminal KEKE motif to the C-
terminus of Rpn13, a proteasomal ubiquitin receptor which ensnares 
polyubiquitinated prey for degradation. UCH37 is known to be catalytically 
activated upon binding to Rpn13, allowing cleavage of Lys48-linked polyubiquitin 
chains from their distal end, an exo-specific deubiquitination. However, free 
UCH37 cleaves polyubiquitin poorly and is believed to be autoinhibited by its C-
xii 
 
terminal UCHL5-like domain, or ULD, which may also be responsible for its 
oligomerization in solution. This work examines the structural, biophysical, and 
catalytic characteristics of UCH37 in order to elucidate its mechanism of 
activation by Rpn13, assess its biophysical assembly with Rpn13 within the 
greater proteasomal context, and ascertain its mechanism of exo-specificity 
despite the proteasome’s processing of a variety of polyubiquitinated substrates.  
To this end, a 1.7 Å resolution X-ray crystal structure was solved of the 
catalytic domain of a UCH37 homolog from Trichinella spiralis in complex with 
ubiquitin vinyl methyl ester (UbVME), a suicide inhibitor substrate. Our structure, 
in combination with another solved of a longer construct of TsUCH37 in complex 
with UbVME, provided structural insights into the ability of UCH37 to process 
polyubiquitin, namely that its C-terminal UCHL5-like domain (ULD) is responsible 
for its exo-specific activity due to a network of interactions with ubiquitin’s Lys48. 
Through biophysical and kinetic characterization, we have affirmed the 
poor activity of UCH37 alone, but do not ascribe it to autoinhibition because it 
does not oligomerize as previously thought, rather we find that it sediments in a 
monomer-dimer equilibrium in analytical ultracentrifugation experiments. We 
have characterized its binding and activation by Rpn13, finding that UCH37 binds 
to Rpn13 with a 22 nM dissociation constant and that mutations to UCH37’s ULD 
render it unable to be activated by Rpn13. Interestingly, we have found that while 
Rpn13 activates UCH37 for ubiquitin-AMC cleavage, a monoubiquitin fluorogenic 
substrate, it appears to slow the enzyme’s processing of Lys48-linked 
polyubiquitin chains in our assays. 
xiii 
 
Altogether, we have confirmed that UCH37 exists primarily as a monomer 
which binds tightly to its proteasomal subunit, Rpn13, and can exo-specifically 
cleave Lys48-linked polyubiquitin chains.  However, UCH37 may not be activated 
as was previously thought, by Rpn13 alone, and likely requires full association 





CHAPTER 1: INTRODUCTION 
 
1.1 Ubiquitination 
 Ubiquitination occurs through a coordinated enzymatic cascade ending in 
the attachment of ubiquitin’s C-terminal glycine (Gly76) to an acceptor lysine 
residue via an isopeptide bond. This is achieved through sequential ubiquitin 
activation (E1 enzymes), conjugation (E2 enzymes), and ligation (E3 enzymes). 
The E1 enzyme, of which there are only two in humans,  binds both ubiquitin and 
ATP-Mg2+, forms an adenylated ubiquitin intermediate, and then its catalytic 
cysteine attacks this adenylated ubiquitin to form a ubiquitin-charged E1, 
connected by a high energy thioester bond 1. Ubiquitin is then passed on to one 
of about 40 E2 enzymes by attack of their catalytic cysteine to form a charged E2 
2. Subsequently, the charged E2 binds to one of hundreds of E3 enzymes, which 
then permits ubiquitin ligation onto a target protein either through direct transfer 
from the E2 onto the substrate, or by E2 hand-off to the E3 enzyme, which itself 
ligates the ubiquitin onto an acceptor lysine (Fig. 1.1) 2. The determinant of either 
of these two mechanisms is inherent in the E3 enzyme; RING/U-box ligases 
mediate direct E2 transfer, while HECT ligases form a thioester with ubiquitin and 












































































































































































and DNA damage repair. Ubiquitin can also be linked through its start methionine 
to form linear ubiquitin chains, which are involved in NF-κB activation as well as 
cell death 10.  Additionally, monoubiquitination serves as a signal for a variety of 
cellular events, notably transcriptional regulation and degradation of membrane 
proteins 11-13. Currently, little is known about the biological function of chains 
linked through K6, K27, K29, and K33 14. Adding further complexity to the 
system, ubiquitin chains can be heterotypic, either through mixed ubiquitin chain 
linkages that may be “branched” (mixed chain type) or “forked” (two ubiquitin 
chains stemming from one monomer) chains, or as mixed ubiquitin-SUMO 
chains, all of which are in their early stages of biological characterization 9,15-17. 
The mechanisms by which E2s and E3s recognize, bind, initiate, and elongate 
ubiquitin chains of varying topologies is still under investigation, as well as 
identification of their specific substrates. 
 
1.2 Deubiquitination 
In opposition to ubiquitination lies deubiquitination, the hydrolysis of the 
isopeptide bond (or Met1-linked amide bonds in linear polyubiquitin) and 
subsequent release of ubiquitin from its substrate (Fig. 1.1). This is achieved by a 
~100-membered group of enzymes called deubiquitinases, or DUBs. They are 
further broken down into mechanistic families, the cysteine proteases and the 
metallo-proteases. Cysteine DUBs hydrolyze isopeptide bonds utilizing catalytic 



































































































































polyubiquitin chains. Other DUBs have specificity for the substrate which has 
been ubiquitinated. DUBs that are responsible for chain cleavage have further 
specificity for the directionality of their cleavage activity: some remove whole 
chains from the site of attachment to a substrate, called en bloc cleavage; some 
cleave in the middle of a chain, or endo specificity; and the third group cleaves 
from the furthest end of the chain (distal monomer) and removes monomers 
sequentially, exo-specific cleavage (Fig. 1.3) 18. 
In addition to their DUB domains, many deubiquitinases contain ubiquitin 
binding domains (UBDs) which either provide additional stabilization to ubiquitin 
binding or confer specificity. Typically, these domains bind monoubiquitin, 
sometimes polyubiquitin, with weak affinity in the high micromolar range. They 
are most efficient at improving ubiquitin binding when multiple UBDs are found in 
one DUB, or if a DUB within a larger complex binds to other proteins containing 
UBDs 18,19.  Examples of some of the most frequently-occurring UBDs are UBAs 
(ubiquitin associated domains), UIMs (ubiquitin interacting motifs), and ZnFs 
(zinc  finger ubiquitin binding domains) 19. UBDs are crucial for the activity of 
many deubiquitinases and are also critical regulators of ubiquitin binding across 
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C-terminal extension was named the ULD, or UCHL5-like domain, which is 
believed to autoinhibit the enzyme’s catalytic activity. At the end lies its KEKE 
motif, a region responsible for its binding to the 26S proteasome through the 
proteasomal subunit Rpn13, which has a complementary KEKE motif of its own 
21,22,31,32. BAP1 has a putative ULD domain, by sequence similarity, which has yet 
to be characterized 24,33. BAP1 additionally has a nuclear localization signal at its 
far C-terminal end responsible for its cellular localization 24. Both UCH37 and 
BAP1 are known to process larger substrates than UCHL1 and UCHL3; UCH37 
disassembles polyubiquitin chains at the 26S proteasome, while BAP1 
deubiquitinates histone H2A as part of the Polycomb repressor DUB complex 
(PR-DUB) 25,26,34,35. UCH37 has been found within the assembly of another 
macromolecular complex, the Ino80 chromatin remodeling complex, where it 
exists in a generally inactive form, the role of which has yet to be explored 36. 
This study focuses on the activity of UCH37, especially as it relates to its role at 
the 26S proteasome. 
 
1.3 The 26S Proteasome 
The 26S proteasome is a 2.5 MDa proteolytic machine responsible for 
degrading the majority of cellular proteins 37-39. It consists of a 20S core particle 
composed of proteolytic enzymes and a 19S regulatory particle responsible for 
capturing and feeding ubiquitinated proteins into the mouth of the 20S. The 20S 
is made up of 4 stacked heptameric rings of structurally similar, but not identical, 
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event is achieved by the 19S regulatory particle’s AAA ATPase subunits, Rpts 1-
6, a heterohexameric motor which utilizes ATP hydrolysis to pull polypeptide 
chains into the 20S (Fig. 1.6). These Rpts dock to the outer α rings of the 20S 
and serve as the base of the 19S RP. Studies of other AAA unfoldases, 
especially ClpXP, a bacterial unfoldase, has suggested that translocation and 
unfolding are simultaneously achieved through bursts of mechanical force 52,53. 
Both ClpXP and the φ29 DNA packaging motor have been shown to exist 90% of 
the time in a dwell state, with only 10% of its time spent in a burst of activity 53,54. 
This has yet to be confirmed in the 26S Rpts, but cryoEM structures of the Rpts 
engaged and disengaged with substrate suggest this may be the case 48-50,55,56. 
 In addition to Rpts 1-6, the base of the 19S regulatory particle contains 
two scaffolding proteins, Rpn1 and Rpn2, as well as the two constitutive ubiquitin 
receptors, Rpn10 and Rpn13 39,57. Rpn1 and Rpn2 act to recruit associated 
proteins and shuttle factors to the 19S. Through interactions with Ubl (ubiquitin-
like) domains, Rpn1 acts as a docking site for shuttle factors which bring 
polyubiquitinated proteins to the proteasome, such as Rad23B and Dsk2 58-61. 
Rpn1 is also responsible for recruitment of one of the proteasome’s associated 
deubiquitinating enzymes, USP14, discussed below. Thus far, Rpn2 is only 
known to anchor one of the intrinsic proteasomal ubiquitin receptors, Rpn13, to 
the proteasome, no other shuttle factors or associating ubiquitin receptors 57,61-64. 
 Rpn10 and Rpn13 are the intrinsic ubiquitin receptors at the proteasome, 
although shuttle factors and some temporarily-associating ubiquitin receptors 
(Rad23B, Dsk2, Dss1, Ddi1, AIRAP) also bind polyubiquitin and transport it to the 
12 
 
proteasome 58,65,66. Interestingly, deletion of these receptors and shuttle factors 
(currently known ones) does not impair growth of yeast 60,64. Rpn10 and Rpn13 
bind tightly to the proteasome, whereas the other shuttle factors bind weakly and 
transiently 61,63. It is possible that there are even more shuttle factors or receptors 
to be discovered that may rescue protein degradation upon deletion of this set. 
Rpn10, or S5a in humans, utilizes two ubiquitin interacting motifs (UIMs) to bind 
polyubiquitin avidly and can also recruit the shuttle factor Rad23B 57,58,67-72. It has 
an additional N-terminal von Willebrand A (VWA) domain of unknown function. 
Rpn13 contains an N-terminal pleckstrin homology domain referred to as the 
pleckstrin-like receptor for ubiquitin (Pru) domain, which binds ubiquitin in a novel 
mode compared to other ubiquitin binding domains 21-23,62-64. Rpn13’s C-terminal 
domain is responsible for binding UCH37, the second proteasome-associated 
deubiquitinase. Rpn10 and Rpn13 lie on the outer edge of the 19S, at opposite 
ends, affording polyubiquitin chains a broad surface area for binding as well as 
the flexibility of multiple conformations and chain branching (Fig. 1.5) 50,56,57. 
Wrapping around and above the 19S base complex lies its lid complex, 
one of the least understood components of the 26S. Functions have not been 
assigned for its 9 subunits except Rpn11, the proteasome’s constitutive 
deubiquitinase. Rpns 3, 5, 6, 7, 9, and 12 contain a proteasome cyclosome 
initiation factor (PCI) domain, but the function of these proteins is currently 
unknown, aside from acting as scaffolds for other components 73. Rpn11, a 
JAMM metallo-DUB, requires dimerization with Rpn8, which contains an inactive 
MPN domain, to form its active deubiquitinating module 55,74-80. The lid sits above 
13 
 
and around the opening pore of the AAA ATPases, with Rpn11 poised 
immediately adjacent to the access point of polyubiquitinated substrates 50,55. 
 
1.3.1 Deubiquitination at the 26S Proteasome 
 After polyubiquitinated proteins are brought to the 26S proteasome via 
shuttle factors and transient ubiquitin receptors, they bind to the proteasome’s 
intrinsic ubiquitin receptors, Rpn13 and Rpn1021,23,57,58,62,81. As substrates are 
unfolded and translocated into the interior of the core particle, the metallo-
deubiquitinase, Rpn11, cleaves off whole ubiquitin chains from the substrate 
protein, releasing them back into the cellular pool of ubiquitin 32,75-77. Rpn11 
utilizes a catalytic zinc ion bound by two histidines and an aspartate to cleave 
polyubiquitin chains in an en bloc fashion, that is, the entire chain is removed 
from its acceptor lysine on a substrate protein74,79. From cryo-EM structures of 
the 26S engaged and free of ubiquitinated substrates, it is known that Rpn11 
initially exists in an occluded state that is misaligned with the central pore and 
ATPases, which subsequently undergoes a dramatic conformational change 
upon substrate binding and engagement 50,55. This conformational change aligns 
the active site of Rpn11 immediately above the central pore and ATPase ring 
opening, which then allows it to cleave entire polyubiquitin chains from an 
engaged substrate protein 50,55. Rpn11 is a highly promiscuous DUB capable of 
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UCH37 and USP14 are cysteine protease DUBs which cleave polyubiquitin 
chains exo-specifically, that is from the furthest monomer (distal) from the 
substrate protein and working their way inwards. USP14 associates with the 
proteasome through its Ubl domain, which binds to Rpn1, a known docking point 
for other Ubl domain-containing proteins. UCH37, however, binds to an ubiquitin 
receptor, Rpn13, through matching KEKE motifs within both of their C-terminal 
domains. USP14 and UCH37 have poor basal levels of deubiquitinase activity 
alone, but become significantly activated upon recruitment to the 26S 
proteasome21,78,84,87,88. They are generally thought to be present in 
substoichiometric amounts at the 26S, especially USP14 due to the fact that its 
binding partner, Rpn1, is known to bind to multiple proteins at that same site. 
Currently it is believed that UCH37 is specific for Lys48-linked chains and that 
USP14 may process other chain types, however, the variety of ubiquitinated 
species brought to the proteasome indicates that these DUBs are probably more 
promiscuous than first thought. 
A few theories exist as to what role these associated DUBs play in 
proteasome degradation: (1) they recycle monoubiquitin, for further use by the 
cell 89,90; (2) they may allow dissociation of chains prior to substrate commitment 
for degradation, and in turn rescue a small portion of proteins slated for 
degradation that may be inappropriately labeled 34,35; or (3) after a polyubiquitin 
chain has been freed from its substrate by Rpn11, the two associated DUBs 
sequentially remove ubiquitin monomers until the affinity of the polyubiquitin 
chain for Rpn10 or Rpn13 is poor enough to dissociate from the 26S, allowing 
16 
 
“resetting” of the proteasome for another round of degradation 39,91. Their 
inhibition has been shown to accelerate proteasomal degradation, however, 
further work is needed to clarify the biological role of proteasome-associated 
deubiquitination 86,92. 
Within this work, we present the X-ray crystal structure of a UCH37 
homolog bound to ubiquitin, as well as biophysical and kinetic data, which 
provides a better structural understanding of the specificity and activation of this 
proteasome-bound DUB. Despite the broad spectrum of ubiquitinated 
proteasomal substrates, this DUB appears to maintain a limited specificity. We 
hope that these studies of UCH37 will obtain a better picture of how 
deubiquitinating enzymes in general balance a need for specificity in the face of a 
plethora of ubiquitinated proteins, as well as how these enzymes are kept in 
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CHAPTER 2: STRUCTURE OF TSUCH37CAT-UBVME 
 
2.1 Introduction 
Structural approaches to studying ubiquitination/deubiquitination 
machinery has yielded extensive information about its detailed mechanisms, 
providing vital understanding of these proteins’ ability to recognize either highly 
specific chain types or to be grossly promiscuous for any ubiquitinated molecule 
available. This approach has given the field incredible insight into the biological 
significance of ubiquitination. The structures of many deubiquitinases have been 
solved alone and in complex with ubiquitin or a ubiquitin variant. Generally, DUBs 
bind monoubiquitin quite poorly, especially if they act as polyubiquitin chain 
trimmers in cells. Therefore, in order to capture a DUB-ubiquitin bound state, 
covalent linkage of monoubiquitin is required, to prevent dissociation during 
crystallography. For this end, a handful of suicide inhibitor ubiquitin variants are 
used in structural biology. One of these is ubiquitin vinyl methyl ester (UbVME), 
used in this study, which seems to have the highest reactivity with UCH family 
DUBs. Here, I have solved the X-ray crystal structure of a UCH37 homolog from 
Trichinella spiralis in complex with ubiquitin vinyl methyl ester. This structure 
highlights the similarities of UCH-family DUB binding to ubiquitin, as many 
contacts are conserved with UCHL1 and UCHL3. However, the active site 
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crossover loop, a structural feature common to UCH enzymes, is not resolved in 
the TsUCH37cat-UbVME structure due to a high amount of flexibility that is not 
abrogated upon ubiquitin binding, an unexpected result that hints at UCH37’s 
mechanism of activation.  
 
2.2 Materials and Methods 
 
2.2.1 Synthesis of Ubiquitin Vinyl Methyl Ester 
 The synthesis of glycine vinyl methyl ester (GlyVME) has been previously 
published, but was modified in our hands (Fig 2.1) 1-3. For the Boc protection 
reaction, 8 grams (88 mmol) of 3-amino-1,2-propanediol was dissolved in 150 mL 
water, then cooled on ice in order to add 23 grams (105 mmol) of di-tert-butyl 
dicarbonate (Boc anhydride), after which the reaction was returned to room 
temperature. Then the reaction was brought to pH 10.5 by addition of sodium 
hydroxide and the reaction was allowed to run overnight at room temperature. 
The reaction was diluted with 100 mL of ethyl acetate, cooled on ice, and then 
brought to pH 2.5 with hydrochloric acid. The product was then extracted out with 
8 x 50 mL ethyl acetate. The organic layer was washed with NaHSO4 and brine, 
dried over sodium sulfate, and then rotovapped down and stored at -20 C. For 
the oxidation reaction, 7-8 g of Boc-propanediol was dissolved in 125 mL water, 
to which 1.4 molar equivalents of NaIO4 were added. The reaction was stirred for 
2-12 hours. The product was extracted out with 3 x 100 mL ethyl acetate, dried 
over sodium sulfate, and then rotovapped down. The aldehyde product was used 
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within a day and stored at -20 C. For the Horner Wadsworth Emmons reaction, 1 
equivalent of sodium hydride (60% suspension in mineral oil) was added to a 
flame-dried round bottom and immediately suspended in 40 mL dry THF, then 
purged with N2. The sodium hydride was washed 3 x 30 mL dry THF and then 1 
equivalent of trimethyl phosphonoacetate was added over 1 hr on ice. Additional 
THF was added as needed to keep the reaction in solution. The Boc-aldehyde 
was dissolved in minimal THF and added to the reaction over 1 hr on ice. After 
addition, the reaction was allowed to warm to room temperature and run from 6-
12 hrs. The reaction was quenched with 200 mL water and then THF was 
removed by rotovapping. The product, Boc-GlyVME, was extracted out with 3 x 
50 mL chloroform and the organic layer was washed once with 50 mL of 2% 
hydrochloric acid and once with 50 mL saturated sodium carbonate. The organic 
layer was dried over sodium sulfate and then rotovapped down and stored until 
purification. Boc-GlyVME was purified by silica flash chromatography using a 
gradient of 0-20% ethyl acetate in hexanes, pooling only fractions containing the 
E isomer. Solvent was rotovapped off, the product was washed 2 x with DCM, 
and then rotovapped down again. For Boc deprotection and crystallization of the 
final product, 2 molar equivalents of p-toluenesulfonic acid was dissolved in 100-
200 mL diethyl ether, dried over sodium sulfate, and decanted off. Boc-GlyVME 
was dissolved in minimal ether and added to the pTSA solution. GlyVME tosyl 
salt crystallized out overnight, was filtered out, and stored at -20 C until reaction 
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the column to displace Ub1-75 from the intein group by incubating overnight at 
37°C. The eluate was collected and concentrated down to 1.5 mL. 
 In order to generate UbVME, UbMESNa was incubated with 200 mg 
GlyVME and 125 mg NHS dissolved in 1 M NaHCO3 at pH 8 overnight at room 
temperature. After incubation, UbVME was dialyzed into 50 mM NaOAc pH 4.5 
for 4 hours, then applied to a Mono S cation exchange column for purification 
from UbMESNa or hydrolyzed Ub1-75. Fractions were tested for reactivity with 
UCHL3 and the most reactive fractions were pooled, concentrated down, and 
flash frozen and stored at -80°C. 
 
2.2.2 Cloning, Expression, and Protein Purification of TsUCH37cat 
Full-length Trichinella spiralis (Ts) UCH37 in the pET28a vector was sent 
from the lab of Katerina Artavanis-Tsakonas, who had previously identified the 
enzyme as a UCH family member and confirmed it to be UCH37 by co-
immunoprecipitations and pull-downs of proteasomal subunits 4. Following 
standard cloning protocols, the catalytic domain of TsUCH37, residues 1-226, 
was subcloned into the pGEX 6P1 vector between BamHI and XhoI digestion 
sites. The protein was expressed in E. coli Rosetta DE3 cells to an O.D. of 1.0 
and the cells were harvested after expression overnight at 18°C. Cells were lysed 
by French press and spun down at 100,000 x g for 1 hour. The supernatant was 
applied to glutathione sepharose beads and unbound proteins were washed off 
with column buffer (1 x PBS, 400 mM KCl). GST-fused TsUCH37cat was eluted 
with reduced glutathione and incubated with PreScission Protease (GE 
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Biosciences) overnight at 4°C. TsUCH37cat was run back over the glutathione 
beads to capture GST, and then the pure protein was concentrated down and run 
on a HiLoad Superdex 75 for further purification. Pure fractions were 
concentrated down, flash frozen, and stored at -80°C. 
 
 
2.2.3 Complexation of TsUCH37cat with UbVME 
 Test reactions to complex TsUCH37cat with UbVME were set up in 12 uL 
scale to determine the ideal concentration to push complexation to completion. 
Three tests were done at 37°C for 3 hours at 29 mg/mL, 14.4 mg/mL, and 9.6 
mg/mL TsUCH37cat (Fig. 2.2). For the final scale up reaction, 14.4 mg/mL was 
chosen. The scale-up reaction was composed of 600 uL of 14.4 mg/mL 
TsUCH37cat, 600 uL UbVME, and 70 uL 1M Tris pH 8.0, for a total volume of 1.9 
mL (Fig. 2.2). After 3 hours at 37°C, the reaction was diluted to 4 mL and run on 
a Superdex 75 for further purification, but an unexpected higher molecular weight 
species was not purified, so all fractions from this step were pooled, buffer 
exchanged, and run on a MonoQ anion exchange column in 0-40% 50 mM Tris 
pH 7.6, 1 M NaCl, 1 mM DTT over 45 column volumes. The pure complex eluted 
at 17% 1 M NaCl (Fig. 2.2). Pure fractions were pooled, concentrated down to 3-
















































































































that each buffer was supplemented with 2-5 mM DTT to keep selenomethionine 
in a reducing environment. Mass spectrometry of SeMet TsUCH37cat by protein 
MALDI confirmed that all four methionines in the protein were enriched with 
SeMet, an M+1 molecular weight of 26238.6 Da and M+2 of 13117.1 Da, with a 
calculated molecular weight of 26238 Da. SeMet TsUCH37cat was complexed 
with UbVME and purified by MonoQ anion exchange chromatography. Pure 
fractions were pooled, concentrated down, and flash frozen and stored at -80°C. 
Yields for the SeMet protein were reduced; therefore the SeMet complex was 
lower concentration than the original complex. 
 
 
2.2.5 Crystallization and Structure Solution 
 Native TsUCH37cat-UbVME was screened at 3 mg/mL in ~700 
crystallographic conditions by sitting drop vapor diffusion. A hit was identified in 
the Hampton Research Ammonium Sulfate grid screen, composed of 3 M 
ammonium sulfate, 0.1 M bicine pH 9 at room temperature after 2 days by 
hanging drop vapor diffusion. However, rather than single, 3D crystals, the initial 
hit appeared to be stacks of 2D plate crystals. In anticipation of poor data due to 
multi-latticed crystals, the initial hit was optimized by additive screening. Single 
3D crystals appeared with the addition of 2 mM glutathione (mixture of oxidized 
and reduced). Crystallization attempts with the SeMet complex in the same 
mother liquor composition as the native hit did not yield any crystals, therefore 
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 The initial model was obtained from the Phenix AutoSol wizard using 
selenium SAD phases with an input of 8 Se sites (from Matthews coefficient, 
determined to be a dimer in the asymmetric unit). The initial model was given a 
FOM (figure of merit) of 0.338, and initial Rwork of 0.3695 and Rfree of 0.3884. Its 
sequence was built in using the Phenix AutoBuild wizard with additional manual 
model building in Coot 7,8. Two copies of the complex were found in the 
asymmetric unit, having a space group of C2. Refinement of the structure was 
done in Phenix using some TLS refinement (entire asymmetric unit considered to 
be one TLS group) and optimized weighting for stereochemical restraints 7. 
Overall completeness of the data was poor, at 88.5%, but this can be credited to 
poor completeness in the highest resolution shells (42%), which did not prevent 
structure solution or refinement. The final model had an R factor of 17.4% and an 
Rfree of 21% with <0.2% of residues in the disallowed region of the 
Ramachandran plot and scoring a 98% in assessment by Molprobity 9. The 














2.3.1 Structure of TsUCH37cat-UbVME 
TsUCH37cat-UbVME crystallized in the C2 space group with two copies of 
the complex in the asymmetric unit. The final model had an R factor of 17.4% 
and an Rfree of 21% (Table 2.1).  
The first structural element to come to our attention was the presence of 
electron density for a disulfide bond between Cys71 of each TsUCH37cat 
monomer, leading to disulfide-mediated dimerization in the asymmetric unit. 
Human UCH37 was previously thought to oligomerize in solution through its C-
terminal domain, therefore this result was unexpected. In order to determine if 
this dimerization has biological relevance, the TsUCH37cat-UbVME complex and 
TsUCH37cat alone were both subjected to analytical ultracentrifugation, the 
results of which are discussed in Section 3.3. We concluded that this disulfide 
bond formation was a crystallographic artifact rather than a biologically significant 
event. It likely arose as a result of the introduction of glutathione as an additive 
and may have assisted crystal packing into a better form than the initial 2D plate 
crystals. The two copies of the complex have an RMSD of 0.39, indicating very 
few differences between them. Analysis of the complex, for the purpose of this 
document, will focus on Chains A and B in the PDB file rather than the copy, 
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of the tail as well as Arg72 and Arg74’s side chains. The active site tetrad, 
composed of Cys85, Asp176, His161, and the oxyanion-stabilizing residue 
Gln79, is arranged in a canonical orientation for the UCH family, which is seen in 
papain-like cysteine proteases as well. The catalytic Cys85 of TsUCH37 has 
flipped about 90° compared to Cys88 of the unbound human enzyme (PDB 
3IHR) upon binding to GlyVME, a mimic of the acyl-enzyme intermediate during 
catalysis. This phenomenon is also seen in the ubiquitin-bound and unbound 
structures of UCHL1, and is believed to be a conformational switch from an 
unproductive form of the enzyme that may exist as a protective mechanism 12. 
Some deubiquitinases operate within an oxidative environment, and this 
conformational change may protect the enzyme against cysteine oxidation 14.  
 
2.3.3 Distal Site Binding 
Stabilization of ubiquitin’s C-terminal tail is the primary mode of ubiquitin 
binding by UCH family enzymes, with the second-most important being its distal 
site interactions with ubiquitin’s Leu8, Thr7, and Thr9 as well as ubiquitin’s Ile44 
patch. Ubiquitin-interacting residues from the Ts to human UCH37 are not highly 
conserved compared to its catalytic cleft residues. The distal site of TsUCH37 
utilizes different hydrophobic groups than the human enzyme for ubiquitin 
binding, such as replacement of Ser37 with Leu36 and substitution of the large 
Trp36 with Val34 and Val35 (Fig 2.6). Additionally, comparing the distal pockets 
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make any contacts with ubiquitin in the situation of this complex: UCH37 – 
monoubiquitin. This leads one to believe that an additional protein binding event 
would be required to stabilize the crossover loop, that it may require a different 
minimal substrate (diubiquitin, triubiquitin, etc) or that the crossover loop binds to 
another protein regulator. We speculate that this other protein may be Rpn13, 




 Here we have presented the structure of TsUCH37cat bound to ubiquitin 
vinyl methyl ester, which has provided some valuable insights into the 
mechanism of this UCH family deubiquitinase. The enzyme relies on a complex 
network of interactions around ubiquitin’s C-terminal tail for substrate 
stabilization, which is highly conserved between TsUCH37 and the other yeast 
and human homologs of UCH enzymes. Additionally, TsUCH37 utilizes distal site 
binding to recognize ubiquitin’s Ile44 patch and Leu8-Thr9 motif. However, the 
residues responsible for distal site binding are not as conserved as those in the 
catalytic cleft, compared to human UCH37. This lack of conservation may impact 
the affinity of ubiquitin binding, which will be explored in Part 2 through 
comparison of the enzyme’s catalytic activity compared to the human enzyme. 
This region of the enzyme may confer selectivity among UCH family enzymes, 
distinguishing each from one another, as their catalytic clefts are nearly identical.  
44 
 
 The most significant structural difference between TsUCH37cat and the 
other UCH family structures is that its crossover loop has not gained sufficient 
stabilization upon ubiquitin binding to be visualized in its X-ray crystal structure. 
The crossover loop is a structural element of UCH enzymes which is responsible 
for substrate filtering and binding, which appears to not play a role in ubiquitin 
binding for TsUCH37, and likely human UCH37 as well. We speculate that the 
crossover loop would be resolved in the structure if it was satisfying all its 
necessary contacts, which probably requires binding to an additional partner. We 
further hypothesize that this binding partner may be Rpn13, the proteasomal 
subunit which anchors UCH37 to the 26S proteasome. It seems therefore that 
the crossover loop in UCH37 may be a key element in the regulation of UCH37’s 
catalytic activity through protein-protein contacts. Further examination of the 
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 The biophysical characteristics of UCH37 keenly regulate its kinetic 
activity as well as biological association with its proteasomal binding partner, 
Rpn13. Its ULD, or UCHL5-like domain, has been shown to alter its activity and 
ability to bind to the 26S proteasome. Within this ULD lies the KEKE motif, a 
region spanning the final 20-30 amino acids of the protein, which is responsible 
for its binding to the proteasomal subunit Rpn13. Rpn13 harbors a 
complementary C-terminal KEKE motif, which binds to UCH37 (Fig 3.1). 
Interestingly, the ULD of UCH37 is also thought to play two additional roles within 
the enzyme: (1) regulation of its oligomeric state and (2) autoinhibition of the 
enzyme’s catalysis1-5. The oligomerization of UCH37 was explained by 
tetramerization of the human enzyme in its X-ray crystal structure (PDB ID 3IHR) 
as well as in-solution higher order oligomers observed during size-exclusion 
chromatography (Fig 3.2) 5. Autoinhibition has been seen by multiple groups in 
the context of purified protein, by deletion of the ULD and comparison of its 
activity versus that of the full-length enzyme against ubiquitin 7-amino-4-
methylcoumarin, a fluorogenic monoubiquitin substrate standard in the DUB field, 
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characteristics of the event, we are still unclear about how the enzyme transitions 
between its basal and activated states. 
 
3.2 Materials and Methods 
 
3.2.1 Cloning, Expression, and Protein Purification 
 TsUCH37cat and TsUCH37cat-UbVME were purified as described 
previously in Part 2.2.2. TsUCH37FL with an N-terminal 6xHis tag in pET28a+ 
was expressed in E. coli by Dr. Myung-Il Kim as described in Morrow et. al, 2013 
10. For isothermal titration calorimetry, human Rpn13 was expressed and purified 
by Dr. Judith Ronau from E. coli on glutathione beads and subsequently by size 
exclusion chromatography. Human UCH37 proteins used for isothermal titration 
calorimetry were wild-type and an E284A mutant (discussed further in Section 
4.3.2), both expressed from a pET28a+ plasmid in E. coli, purified on Ni-NTA 
beads using a 50 – 500 mM imidazole gradient (purification buffer of 20 mM 
sodium phosphate pH 7.0, 300 mM NaCl, ). Due to an engineered HRV 3C 
protease site, Prescission Protease (GE Biosciences) was added to remove the 
6xHis tag and linker, which was subsequently removed by incubation with 
glutathione beads. Second step purification was done on both wild-type and 
UCH37 E284A on a Sephadex S200 size exclusion column (GE Biosciences) 




3.2.2  Analytical Ultracentrifugation 
 TsUCH37cat and TsUCH37cat-UbVME were both dialyzed extensively 
against 50 mM Tris pH 7.4, 200 mM NaCl, and 1 mM DTT. Samples were run at 
concentrations a range of concentrations: 8, 16, and 32 µM for TsUCH37cat and 
10, 18, and 31 µM for TsUCH37cat-UbVME to determine oligomeric states at high 
concentrations. Samples were run on a Beckman-Coulter XLA analytical 
ultracentrifuge at 50,000 rpm and monitored at 280 nm for 150 scans. 
Sedimentation coefficient distributions were analyzed by SEDFIT (v. 13.0b) 11. 
For analysis of human UCH37 and Rpn13, proteins were both extensively 
dialyzed against 50 mM Tris pH 7.5, 50 mM NaCl, 1 mM TCEP. For analysis of 
individual oligomerization states, UCH37 was run at 8, 16, and 32 µM and Rpn13 
was run at 13.5, 27, and 54 µM. Analysis of the UCH37-Rpn13 complex was run 
at concentrations of 4 and 8 µM, 4 and 16 µM, and 4 and 32 µM of UCH37 and 
Rpn13, respectively. Samples were run and analyzed by the same methods as 
TsUCH37cat and TsUCH37cat-UbVME, above. 
 
3.2.3 Ubiquitin-AMC Hydrolysis 
 Cleavage of 7-amino-4-methylcoumarin from the C-terminus of 
monoubiquitin, or UbAMC cleavage, was monitored in a reaction buffer 
containing 50 mM Tris pH 7.6, 0.5 mM EDTA, 0.1% bovine serum albumin, and 5 
mM DTT. TsUCH37cat and TsUCH37FL were diluted in reaction buffer to 7 nM 
final reaction concentration and preincubated at 30°C for 5 minutes prior to the 
reaction. Reactions were initiated by addition of UbAMC (Boston Biochem) and 
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were measured on a Tecan fluorescence plate reader (Männedorf, Switzerland) 
with 380 nm excitation wavelength and 465 nm emission wavelength at 30°C for 
1 hr. Progress curves and Michaelis-Menten kinetics were plotted and fit in 
SigmaPlot (Systat Software). 
 
3.2.4 Isothermal Titration Calorimetry 
 For isothermal titration calorimetry, wild-type UCH37, UCH37 E284A, and 
Rpn13 were dialyzed extensively together against 50 mM Tris pH 7.5, 50 mM 
NaCl, 1 mM TCEP. ITC experiments were done using a MicroCal ITC200 (GE 
Biosciences). For determination of the Kd of UCH37 wild-type and Rpn13 
binding, two experiments were averaged together: 20 µM UCH37 in the cell with 
228 µM Rpn13 injected, and 10 µM UCH37 in the cell with 100 µM Rpn13 
injected. For UCH37 E284A, 10 µM E284A was in the cell and 100 µM Rpn13 
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At concentrations higher than that in cells (8 – 32 µM), neither TsUCH37cat nor 
the TsUCH37cat-UbVME complex were found to exist in solution as dimers. Both 
are monomeric, with sedimentation coefficients (S20,w) of 3.3 for the complex and 
2.8 for the catalytic domain (Fig. 3.3). Therefore, the dimerization event observed 
in the crystal structure is an artifact of crystal packing, mediated by disulfide bond 
formation resulting from oxidative conditions prevailing in the crystallization buffer 
(glutathione additive). 
 
3.3.2 Kinetic Characterization of TsUCH37cat and TsUCH37FL 
In order to characterize the catalytic activity of TsUCH37, its activity 
against a standard DUB substrate, a fluorogenic monoubiquitin derivative called 
UbAMC, was assessed. The original goal of studying TsUCH37 previously was 
for drug targeting12, therefore, it was of interest to examine its catalytic 
mechanism compared to that of human UCH37 and the other UCH family DUBs. 
Compared to the catalytic domain of human UCH37, TsUCH37cat has about a 20-
fold lower KM, indicating an improvement in substrate binding, however, the kcat 
was 100-fold lower, yielding an overall 5-fold decrease in efficiency of the 
enzyme (Fig 3.4) 9. It would appear that TsUCH37’s catalytic domain binds 
substrate tighter, but that may also impair its ability to dissociate product for 
another round of catalysis. Not surprisingly, TsUCH37cat’s KM is about 14-fold 
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3.3.3 Analysis of UCH37 Oligomeric State 
 In order to probe whether the previously proposed model of UCH37 
tetramerization or higher order oligomerization was possible, we examined its 
oligomerization by analytical ultracentrifugation (Fig 3.5) 5. Additionally, the 
stoichiometry of the binding of UCH37 to Rpn13, its proteasomal binding partner, 
was determined. Analytical ultracentrifugation of UCH37 alone at 8, 16, and 32 
µM yielded data indicating that the enzyme primarily exists as a monomer at 
lower concentrations, but is capable of a concentration-dependent rapid 
monomer-dimer equilibrium, which is seen most prominently in the 32 µM 
concentration sample. Higher order oligomers were not detected at that those 
concentrations, which does not rule out the possibility, but indicates that at 
cellular concentrations, the enzyme is likely monomeric. 
As for the UCH37-Rpn13 complex, first the solution state of Rpn13 was 
determined alone at 13.5, 27, and 54 µM. Rpn13 primarily exists as a monomer 
with a small population of higher order oligomers or aggregates, however this 
proportion is quite small. The UCH37-Rpn13 complex was run at three different 
concentrations of Rpn13 (8, 16, and 32 µM), but with UCH37 fixed at 4 µM. The 
complex exists in a 1:1 stoichiometry, which is not a surprise given that Rpn13 
only has one recognition motif for UCH37 to bind. These results do not appear to 
support the theory that Rpn13 may relieve UCH37 of its autoinhibition through 
binding its ULD to change the oligomeric state of the enzyme. Both proteins are 





































 at the ye























































































wild-type, one with 20 µM UCH37 in the cell and 228 µM Rpn13 as the titrant, 
and a second with 10 µM UCH37 in the cell and 100 µM Rpn13 as the titrant. 
The average Kd was 22 ± 6 nM. UCH37 E284A was only run as a single 
experiment, with 10 µM E284A in the cell and 100 µM Rpn13 injected, which 
yielded a Kd of 18.5 ± 7 nM. Although UCH37 in cells is known to exist as a 
population of free enzyme, not bound to the 26S proteasome and can associate 
with the Ino80 chromatin remodeling complex, these dissociation constants 
suggest very tight binding between this DUB and its proteasomal anchor, Rpn13 
2. This interaction is known to be abolished upon deletion of UCH37’s KEKE 
motif, and it is clear that even though the ULD mutation E284A impairs activation 
of the enzyme (Section 4.3.2), the ULD region likely does not contribute 
significantly to binding to Rpn13 1,6-8. Additionally, as the Kd of UCH37-Rpn13 




 Thorough characterization of UCH37’s kinetic and biophysical properties 
is necessary to dissect its cellular association with the 26S proteasome and 
potential autoinhibition. These studies have shed more light on the role of its ULD 
in catalysis and binding, but more work is still needed to understand its 
activation. We have confirmed that dimerization of the TsUCH37cat-UbVME 
complex in its crystal structure is a crystallographic artifact of tight packing. Our 
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USP14, Ubp6, has two possible binding sites on Rpn1, one a tighter 62 nM Kd 
site, the other much weaker at nearly 2 µM13. Rpn1 is known to bind to shuttle 
factors and other Ubl domain-containing proteins, therefore, USP14 is not always 
bound to it. These numbers would suggest that UCH37 is more frequently found 
in a proteasomal context than USP14 and may play a more significant biological 
role. 
 However, these investigations still leave open the question of how UCH37 
is activated at the proteasome, if it occurs merely through association with a 
conformationally-accessible Rpn13, or if another binding partner is required. A 
UCH37 mutant, E284A, which could not be activated by Rpn13 during ubiquitin-
AMC hydrolysis (Section 4.3.2) bound to Rpn13 with nearly the same Kd as the 
wild-type enzyme. This mutation isolates Rpn13’s activation of UCH37 to an 
event independent of simple binding. Further studies of this mutant in the 
presence of di- or tri-ubiquitin, as well as in the presence of Rpn2, the 
proteasomal subunit which binds Rpn13’s N-terminus, may provide the key to 
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CHAPTER 4: ANALYSIS OF THE TSUCH37∆C46-UBVME STRUCTURE AND 
THE ROLE OF THE ULD 
 
4.1 Introduction 
 Although the TsUCH37cat-UbVME structure provided valuable insight into 
the mechanism of UCH37 and its ability to recognize and bind monoubiquitin, we 
are still lacking information about the role of the ULD in catalysis, binding, and 
activation. However, another group member, Dr. Myung-Il Kim, was able to 
crystallize and solve the structure of a longer construct of TsUCH37 in complex 
with UbVME for us to glean information regarding the ULD, hereafter referred to 
as TsUCH37∆C46-UbVME (Fig 4.1). Due to cleavage of the protein during 
purification, only a portion of the ULD was shown in the structure, but it provided 
important clues regarding ubiquitin recognition by the enzyme. Contacts between 
the catalytic domain of TsUCH37∆C46 and ubiquitin are identical to that of 
TsUCH37cat, including a lack of ordered density for the crossover loop residues. 
However, contacts between ubiquitin and the ULD are seen, making this an 
additional ubiquitin binding interface. These contacts involve hydrogen bonds 
and salt bridge interactions between TsUCH37’s Arg261 and Tyr262 with 
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4.2 Materials and Methods 
 
4.2.1 Molecular Dynamics Simulations 
 A starting model of human UCH37-UbVME was made by modeling of full-
length TsUCH37 using the human UCH37 structure (PDB ID 3IHR) as the search 
model in the SwissModel homology modeling server 2. The final 46 residues 
missing in the TsUCH37∆C46-UbVME were appended from the homology model 
in Coot, which then underwent one round of refinement in Phenix 3,4. Professor 
Markus Lill (Purdue University) then utilized this model for molecular dynamics 
simulations, methods described in Morrow et. al, 2013 5. From the 2 ns 
simulation, snapshots were examined for specific residues’ proximities to 
ubiquitin. The majority of potential interactions could be seen at the 1.3 ns 
snapshot. 
 
4.2.2 Site-directed Mutagenesis and Protein Purification 
 Based on interactions seen in the MD simulations described above, a list 
of Ub-interacting ULD residues were generated from the Ts enzyme and 
corresponding residues in the human enzymes were mutated to Ala. Site-
directed mutagenesis was performed using the AccuPower PCR PreMix 
(Bioneer) and mutations were confirmed by sequencing. Proteins were 
expressed in Rosetta2 DE3 E. coli expression cells and purified by Ni NTA 
beads. After cleavage of the 6xHis tag by Prescission Protease (GE 
Biosciences), proteins were passed over GSH beads to remove the tag and 
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protease. Proteins were further purified by size-exclusion chromatography on a 
Superdex 200 HiLoad column (GE Biosciences). Pure fractions were pooled, 
concentrated down, and flash frozen as aliquots. Concentrations were 
determined by UV/Vis. Human Rpn13FL was provided by Dr. Judith Ronau. 
 
4.2.3 Ubiquitin-AMC Hydrolysis Assays 
Cleavage of 7-amino-4-methylcoumarin from the C-terminus of 
monoubiquitin, or UbAMC cleavage, was monitored in a reaction buffer 
containing 50 mM Tris pH 7.6, 0.5 mM EDTA, 0.1% bovine serum albumin, and 5 
mM DTT. UCH37 wild-type and mutants were pre-incubated with Rpn13 on ice 
for 1 hr, and then diluted in reaction buffer to final reaction concentrations of 0.5 
nM and 15 nM, respectively, and warmed to 30°C for 5 minutes prior to the 
reaction. Reactions were initiated by addition of UbAMC (Boston Biochem) and 
were measured on a Tecan fluorescence plate reader (Männedorf, Switzerland) 
with 380 nm excitation wavelength and 465 nm emission wavelength at 30°C for 







4.2.4 Synthesis of Asymmetric Triubiquitin Substrate and Assays 
 Site-directed mutagenesis was used to introduce a Gly76Val mutation into 
a UbW77 construct in the pGEX-6P-1, which was subsequently confirmed by 
sequencing. The double mutant UbG76V W77 was expressed in Rosetta2 DE3 E. 
coli cells and purified on glutathione beads. After treatment with Prescission 
Protease (GE Biosciences) to remove its N-terminal GST tag, the protein was run 
back over glutathione beads to remove the tag and protease. UbG76V W77 was 
further purified by size exclusion chromatography on a Sephadex 75 HiLoad 
column (GE Biosciences) and pure fractions were pooled, concentrated down, 
and flash frozen as aliquots. 
 Untagged ubiquitin in the pRSET vector was expressed in Rosetta2 DE3 
E. coli cells, spun down, resuspended in purification buffer A (50 mM sodium 
acetate pH 4.5, 2 mM DTT), lysed by French press, heated to 80°C for 10 
minutes, then spun down at 30,000xg for 30 minutes. The supernatant was 
brought to pH 4.5 by 1N HCl and then was purified by cation exchange 
chromatography on SP sepharose beads (GE Biosciences) by gradient elution 
with purification buffer B (same as A, but with 1 M NaCl). Pure fractions were 
pooled and concentrated down, then further buffer exchanged and purified by 
size exclusion chromatography on a Sephadex 75 HiLoad column (GE 
Biosciences) into 50 mM Tris pH 7.6, 50 mM NaCl, 1 mM DTT. Pure fractions 
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 For polyubiquitin cleavage assays, wild-type K48-linked di-, tri-, and tetra-
ubiquitin were generated biosynthetically in the same manner as mutant tri 
UbG76V W77. 1.5 µM wild-type or E284A UCH37 was incubated for 1 hour on ice 
with 50 µM GST-Rpn13 (for triUbG76V W77 assays) or 5 µM untagged Rpn13 (for 
wild-type polyubiquitin assays) in buffer containing 50 mM Tris pH 7.6, 0.5 mM 
EDTA, 0.1% bovine serum albumin, and 5 mM DTT. Reactions were started with 
the addition of 15 µM triUbG76V W77, tetraubiquitin, wild-type triubiquitin, or 
diubiquitin and time points were quenched with SDS PAGE buffer. Reactions 




4.3.1 Analysis of Molecular Dynamics Simulations 
 After Professor Markus Lill (Purdue University) generated a 2 ns molecular 
dynamics simulation for full-length TsUCH37-UbVME, each frame was analyzed 
for potential interactions between the ULD of TsUCH37, the mobile element, and  
ubiquitin, which was held stationary. The majority of interactions were seen at a  
1.3 ns snapshot, showing potential interactions between many ubiquitin-facing 
ULD residues and ubiquitin (Fig. 4.3). Although some interactions are only within  
van der Waals or salt bridge distances, some possible hydrogen bonds were also 
observed. The majority of the residues at this interface are also highly conserved 
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isothermal titration calorimetry (ITC) to determine the binding affinity of E284A 
with Rpn13 compared to wild-type UCH37. The results, shown in Section 3.3.4, 
indicate that binding to Rpn13 is not impaired by this mutation as its Kd is close to 
that of wild-type UCH37. Therefore, this mutation may specifically inhibit the 
mechanism of activation of UCH37 by Rpn13, specifically.  
 Interestingly, ULD mutations near E284 do not impair activation within the 
context of the UbAMC assay, such as R280 and Y281. These two residues are 
not as conserved as E284; R280 is substituted with Met, Lys, or Leu, and Y281 is 
replaced by Trp in lower organisms. Perhaps these residues are more important 
for ubiquitin recognition, rather than activation. 
 
4.3.3 Triubiquitin Cleavage by ULD Mutants 
In order to assess directional cleavage by UCH37, an asymmetric 
polyubiquitin substrate was needed. To this end, UbW77, a construct utilized for 
studies of the activity of UCHL1, was given an additional mutation, Gly76Val, by 
site-directed mutagenesis in order to render its Trp77 non-cleavable by UCH37 8. 
This double mutant monomer can be detected by an HPLC/MS assay due 
to changes in its biochemical properties: 1) increased hydrophobicity and 2) 
increased molecular weight. If ULD mutations abrogated exospecificity, equal 

















































































































Interestingly, Rpn13 appears to slow processing of triUb for both the wild-type 
and E284A UCH37 (Fig 4.6). In the presence of Rpn13, almost no monoubiquitin 
is generated by the two hour timepoint but the monoubiquitin band at the two 
hour timepoint for UCH37 alone is about eight times more intense. Additionally, 
after two hours, UCH37 + Rpn13 still has a significant amount of triubiquitin to 
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 We have analyzed the contribution of UCH37’s ULD and found it to 
provide 1) exo-specificity through binding to ubiquitin’s Lys48 and 2) a means of 
activation of the enzyme through interactions with Rpn13. After analysis of 
ubiquitin-AMC cleavage by ULD mutants in the presence and absence of Rpn13, 
we have identified Glu284 as a critical regulator of Rpn13’s activation, in that 
when it is mutated to Ala, activation is lost. 
 We have generated a novel polyubiquitin for the study of directional-
specific cleavage, triUbG76V W77, which allows detection of a monoubiquitin variant 
by differences in molecular weight, hydrophobicity, and molar absorptivity. We 
have not utilized this triubiquitin for exo-specificity assays yet, but have analyzed 
UCH37’s ability to process tetra-, tri-, and di-ubiquitin in the presence and 
absence of Rpn13. It initially appears that Rpn13 slows polyubiquitin cleavage by 
UCH37, which has been noted by others but not fully explored9. The investigation 
into the mechanism of activation of UCH37 has yet to be completely exhausted, 
especially as it pertains to polyubiquitin cleavage. However, our novel substrate 
has broader uses for other directional-specific deubiquitinating enzymes that 
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CHAPTER 5: RECENT FINDINGS ON THE STRUCTURE AND ACTIVATION 
OF UCH37 AND OTHER DEUBIQUITINASES 
 
5.1 Introduction 
  As of the writing of this document, recent work by two groups has 
uncovered two novel structures of UCH37: (1) bound to its activator, Rpn13, and 
ubiquitin and (2) bound to a fragment of NFRKB, its deactivator and a component 
of the Ino80 complex, both done by Vanderlinden et. al, 2015 and Sahtoe et. al, 
2015 1,2. These papers confirm some of the findings of this work, as well as leave 
some questions open still open about how UCH37 is regulated. This chapter will 
encompass an analysis of the new structures of UCH37 followed by a review of 
deubiquitinating enzymes whose specificity and activation rely on small structural 
elements, such as loops, in the same manner as UCH37. 
 
5.2 Analysis of UCH37-Rpn13-Ub and UCH37-NFRKB-Ub Structures 
 Both structures reveal dramatic conformational changes on the part of 
UCH37’s ULD domain (Fig 5.1) The ULD of apo UCH37 involves a helix-turn-
helix (α9 and α10) followed by a shorter helix, α11, and ending with a short 
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stabilization of an open conformation of the crossover loop likely allows improved 
substrate binding and catalysis, especially for the proximal ubiquitin monomer not 
seen in these structures. Mutations to Met148 and Phe149 render the enzyme 
unable to be activated by Rpn13 in UbAMC assays1,2. It can be predicted that the 
rest of the crossover loop would be visualized in a UCH37-diubiquitin-Rpn13 
structure, and that more of the residues in this region would contribute to 
substrate stabilization at the active site, especially the isopeptide bond. 
Alternatively, it is possible that the cross over loop maintains its dynamic 
character throughout catalytic steps of the enzyme, independent of substrate 
binding. 
 
5.2.2 NFRKB Mode of Inhibition 
The structures of UCH37 bound to the Ino80 component, NFRKB, 
illuminate the way in which the DUB is inhibited catalytically through both its 
active and distal sites. NFRKB hijacks the distal region of UCH37 that binds to 
the Leu8-Thr9 hairpin of ubiquitin, a key motif within ubiquitin for binding. NFRKB 
buries its own Phe100 and Arg101 within the distal pocket, occluding ubiquitin 
binding (Fig 5.3). Additionally, the large helix of NFRKB that lies across the active 
site face of UCH37 induces small conformational strains that lead to an 
unproductive orientation of the active site. The catalytic His has rotated and now 
lies an unproductive 6.3 Å from the catalytic cysteine. All of these small changes 
can be utilized for small-molecule targeting of UCH37, as they directly occupy 



























































5.3 Analysis of Kinetic Findings in Vanderlinden et. al and Sahtoe et. al 
 Interestingly, these groups studied the activation of the enzyme in UbAMC 
hydrolysis assays using one of the ULD mutants discussed earlier, E284A in my 
studies, but numbered E283A in the isoform these groups used. They found that 
Rpn13 lowers the KM of UCH37 for ubiquitin 5-fold, but that the KM of the E283A 
mutant in the presence of Rpn13 is only 1.5-fold improved compared to UCH37 
alone, indicating that this residue may be essential to its activation mechanism, 
similar to the results presented previously (Section 4.3.2)2. These results validate 
our earlier findings, that E284 is essential to the activation mechanism of UCH37. 
 
5.4 Small Structures Effect Large Changes: A Review of Deubiquitinases 
 Among the ~100 deubiquitinating enzymes in the human genome, a little 
less than half of these do not contain auxiliary ubiquitin binding domains or 
ubiquitin-like domains beyond their active sites3. These deubiquitinases must rely 
on conformational movement and binding pockets inherent in their active sites 
alone, or utilize non-canonical interactions with ubiquitin to bind substrate. There 
have been many thorough reviews of the various ubiquitin binding and ubiquitin 
like domains; however, little focus has been drawn to the smaller dynamic 






5.4.1 Unproductive Active Sites 
 One of the simplest, but integral, conformational changes within 
deubiquitinases (DUBs) is the reorientation of catalytic residues from an 
unproductive form in the apo enzyme to a productive conformation upon ubiquitin 
binding. This has been seen in structures of the cysteine protease DUBs and 
frequently involves misaligned catalytic cysteines or histidines within their papain-
like active sites, less often their catalytic aspartic acid or stabilizing oxyanion 
glutamine residues (Fig 5.4).  
Catalytic rearrangement occurs upon ubiquitin binding for the UCH family 
members UCHL19,10 and UCH371,2,11-14. In the apo UCHL1 active site, the 
catalytic histidine resides 8.2 Å away from the catalytic cysteine and is turned 90° 
from the typical orientation of a papain-like active site, an unproductive distance 
for catalysis9. Upon ubiquitin binding, the histidine swings 90° to lay in-plane with 
the catalytic Cys and has moved to a productive 4 Å distance10. In the apo active 
site of UCH37, the catalytic His is in a productive orientation, but its catalytic 
cysteine is rotated inwards, toward the His residue rather than towards the rest of 
the catalytic cleft where ubiquitin will bind11-13. Upon ubiquitin binding, the Cys 
rotates 70° to face Gly76 of ubiquitin, an appropriate conformation1,2,14.  
 Unproductive active sites have been found in the active sites of OTU-
domain containing DUBs as well, both OTU1B, K48-specific, and OTULIN, a 
linear polyubiquitin-cleaving DUB. Upon binding to ubiquitin, OTUB1 has a 
similar conformational change to UCHL1 and UCH37; its His rotates down 90° to 
lock in plane with the catalytic Cys, and its Cys flips inward to face Gly76 of 
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ubiquitin, altogether moving the two residues closer by 3 Å into a catalytically-
productive conformation15,16 (Fig 5.4). The structure of OTULIN’s active site has 
partial occupancy for two distinct orientations: one in which the catalytic His and 
Cys are in appropriate conformations, and one in which the catalytic His is flipped 
to occupy the space which Gly76 resides in the linear diubiquitin-bound 
structure17. 
HAUSP/USP7, one of the most well-characterized USP-family DUBs also 
contains a misaligned active site, wherein its catalytic Cys is positioned 10 Å 
away from the catalytic His (Fig 5.4). Upon ubiquitin binding, its catalytic Cys, 
His, and Asp move closer together, to a 3.7 Å distance between the Cys and His 
and a 2.7 Å distance between the His and Asp. 
The current theory as to why these DUBs prefer a catalytically-
unproductive active site orientation in absence of ubiquitin is that it may protect 
against oxidation18. Some deubiquitinases have been found to be highly 
susceptible to oxidation, which can lead to irreversible modification (sulphinic or 
sulphonic acid) of their catalytic cysteines, rendering the enzyme catalytically 
dead. In the seminal work describing DUB oxidation, the OTU A20 was capable 
of an initial state of reversible oxidation, which would attain irreversibility upon 
continued exposure to the oxidant18. A20 does not have a misaligned active site, 
however it is believed that DUBs with misoriented cysteines may induce 

















































5.4.2 Insertions and the JAMM Domain 
 Regulation of JAMM domain containing deubiquitinating enzymes is 
mainly held by their insertion domains, numbered Ins-1 and Ins-219. The 
insertions act as substrate stabilizers and confer specificity, as seen in the 
structure of AMSH-LP bound to diubiquitin19 (Fig 5.5). AMSH-LP uses the sheets 
of Ins-1 to bind the distal ubiquitin monomer and stabilize the isopeptide bond for 
cleavage, and Ins-2 for additional isopeptide stabilization and binding of the 
proximal ubiquitin monomer. Superposition of the structures of human AMSH, 
another JAMM family DUB, and the AMSH-like S. pombe orthologue Sst2 on the 
AMSH-LP structure shows similar modes of binding and stabilization by their 
highly-conserved insertion domains. These small domains provide significant 
contribution to catalysis; when mutated, they can render the enzyme catalytically 
impaired. However, mutations to Ins-2 do not contribute to substrate binding as 
they only affect kcat, not KM20,21. The isopeptide contacts by the insertions also 
maintain specificity, in that AMSH-LP, AMSH, and Sst2 are all highly specific for 
K63-linked polyubiquitin chains. 
 In contrast, two structures were recently solved for Rpn11, the JAMM DUB 
resident in the 26S proteasome responsible for en bloc cleavage of ubiquitin 
chains from proteasomal substrates, in which only Ins-1 was utilized for substrate 
recognition and catalysis22-24. Ins-2 does not contribute to substrate catalysis; 
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displays an ordered crossover loop that contributes some interactions to 
ubiquitin’s C-terminal tail, buried within the active site (Fig 5.6). Only UCH37 still 
lacks an ordered crossover loop, even in the presence of ubiquitin and its 
activator, the proteasomal subunit Rpn131,2. 
 Through diubiquitin cleavage assays and protein chimeras altering the 
length of the crossover loop, it is apparent that this loop is responsible for 
substrate specificity by steric filtering32,33. Generally, the UCH family is believed 
to only cleave small moieties from the C-terminus of ubiquitin, not processing of 
polyubiquitin. The smaller family members, human UCHL1, human UCHL3, and 
yeast YUH1, which contain solely a UCH domain, have the shortest crossover 
loops and are not capable of polyubiquitin cleavage, only cleavage of ubiquitin-
AMC, a fluorogenic ubiquitin substrate with only the small AMC fluorescent group 
attached to its C-terminus. The two larger UCH family members, UCH37 and 
BAP1, have C-terminal extensions beyond their catalytic domains and contain 
longer crossover loops than the other family members, which is believed to allow 
them to cleave polyubiquitin. A Drosophila homolog of BAP1, Calypso, has been 
shown to deubiquitinate histone H2B34 and UCH37 is proteasome-bound, and 
therefore must process the variety of polyubiquitinated prey captured by the 26S. 
The substrate-filtering theory was proven by an elegant experiment in which the 
crossover loop of UCH37 was expanded by a poly-glycine insertion32. This 
chimeric DUB was capable of both K48- and K63-polyubiquitin chain cleavage32. 
Within that same study, the crossover loop of wild-type UCHL3 was 
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known case of this is seen in the structures of USP14 alone and bound to 
ubiquitin-aldehyde35. In its apo form, USP14’s active site is blocked by two loops, 
BL1 and BL2, which occupy a portion of the space where ubiquitin’s C-terminal 
tail would bind in order to access its catalytic cysteine (Fig 5.7). Upon binding to 
ubiquitin, the entirety of these loops, as well as individual side chains, open up to 
allow ubiquitin binding. Oddly, many of the residues within these loops are also 
responsible for ubiquitin binding, such as Tyr333 and Phe331. These loops are 
attributed to USP14’s poor reactivity with ubiquitin probes, namely ubiquitin-vinyl 
sulfone, but that it becomes activated upon association with the 26S proteasome, 
potentially through conformational restrains of these loops into a more open 
form35. Although many other USP family DUBs contain loops within this region, 
such as HAUSP/USP7, they do not sterically block those USPs active sites. It is 
believed that the length and conformation of these loops confer USP14 with 
unique reactivity compared to other USP family DUBs. 
 
5.5 Conclusions 
 Through examination of the recent UCH37 activating and deactivating x-
ray crystal structures as well as an assessment of other small conformational 
contributions to the regulation of deubiquitinating enzymes, we have a newfound 
appreciation for the layers of specificity and mechanisms of action of DUBs, a 
class of enzymes which process an incredible variety of cellular substrates. Only 
~100 DUBs specifically recognize monoubiquitinated substrates, 8 homotypic 
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chain types, and a startling number of mixed linkage chain possibilities. Even 
more shocking is that only half of them require additional ubiquitin binding 
domains beyond their catalytic core in order to attain specificity and improve 
substrate binding. DUBs containing only a catalytic domain rely on small 
structures within themselves to restrict absolute specificity, as in the case of the 
JAMM DUBs AMSH and AMSH-LP, or to allow processing of a broad spectrum 
of substrates at a highly specific location and under certain conditions, as in the 
case of the proteasomal DUBs Rpn11, USP14, and UCH37. 
 Although we have uncovered significant information regarding the binding 
and catalysis of ubiquitin, as well as the binding and activation of Rpn13, to 
UCH37, many questions still remain regarding its ability to process polyubiquitin 
at the 26S proteasome. Despite our structural findings regarding its exo-specific 
recognition of Lys48-linked chains, it is highly implausible that UCH37 would 
have such limited polyubiquitin processing skills at the proteasome, with 
increasing reports of proteasome processing of non-canonical ubiquitin 
signals36,37. Further structural and biochemical studies of UCH37 within the 
context of the 26S proteasome are needed to understand its role in the coupling 
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  Although UCH37 is capable of activation by Rpn13 alone, its 
activity is further enhanced within the context of the entire 26S proteasome, a 
mechanism of activation which remains a mystery1-3. Due to UCH37’s poor 
cleavage of di- or polyubiquitin substrates alone and in the presence of Rpn13, it 
became clear that activity assays would not succeed without the entire 26S 
proteasome present as an activator. To this end, we pursued purification of 
endogenous 26S from rabbit tissue using an affinity-tag method developed by the 
Goldberg group4,5. Using this proteasome, we hoped to study the roles of the 
deubiquitinases UCH37 and USP14 within overall protein degradation and 
whether their activities are coupled to the rate of degradation of polyubiquitinated 
substrates. 
 This purification method relies on the affinity of the Rpn1 and Rpn10 
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centrifugation method or the TAP- or FLAG-tagged Rpn11 method, allowing 
association of transient factors and ensuring the presence of the associated 
deubiquitinases, UCH37 and USP144,5. This purification method is outlined in 
Figure 6.1. 
 The goal of this purification method is to investigate the contribution of 
UCH37 and USP14 to proteasomal degradation. There is evidence for the role of 
USP14 from purified S. cerevisiae proteasomes, however, these lack UCH378,9. 
The goal of the following work is to understand how inhibition of UCH37 and 
USP14, achieved by incubation with the suicide inhibitor UbVME, affects 




6.2.1 Purification of Rabbit 26S Proteasomes 
 Following the method established by Besche et. al, we purified 
endogenous levels of 26S proteasome from rabbit tissue (Pel-freez)4,5. This 
affinity-tag method relied on the affinity of the proteasomal shuttle factor, 
Rad23B, specifically its Ubl domain, for either Rpn10’s UIM domain or Rpn1’s 
Ubl-binding site6,7. 2-4 grams of rabbit muscle tissue were homogenized on ice in 
proteasome purification buffer (25 mM HEPES pH 7.5, 50 mM NaCl, 5 mM 
MgCl2, 10% glycerol), PB, to which 1 mM ATP and 1 mM DTT were added, and 
then were spun down at 100,000xg for 1 hour. 2 mg of GST-tagged Rad23B Ubl, 
which had been previously purified recombinantly from E. coli, was immobilized 
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on glutathione beads and any excess washed off with PB. Rabbit lysate was 
rocked with immobilized GST-Ubl for 2 hours at 4°C. Beads were collected in an 
empty glass column and unbound proteins were allowed to flow through. 20 
column volumes of PB with added ATP and DTT were used to wash the beads. 2 
mg of 6xHis-tagged Rpn10 UIM was added to the beads and was rocked 
overnight at 4°C to induce elution of pure proteasomes. Proteasomes were then 
run over Ni NTA beads to re-capture the His-UIM. Pure proteasomes were 
concentrated down and flash frozen as aliquots. 
 
6.2.2 20S Activity Assays 
 To confirm the presence of the 20S core particle and test its activity, the 
hydrolysis of succinate-Leu-Leu-Val-Tyr-AMC, a known 20S substrate, was 
measured in the presence of rabbit 26S proteasomes. Suc-LLVY-AMC was 
dissolved in DMSO. 5 nM 26S proteasome was diluted in AMC assay buffer 
containing 50 mM Tris pH 7.6, 0.5 mM EDTA, 0.1% bovine serum albumin, and 5 
mM DTT and allowed to reach 30°C. 100 µM Suc-LLVY-AMC was added to 5 nM 
proteasome in assay buffer and AMC hydrolysis was measured on a Tecan plate 
reader at 380 nm excitation wavelength and 465 nm emission wavelength at 





6.2.3 Ubiquitin-AMC Hydrolysis Assays 
 To test the deubiquitinating activity of endogenous UCH37 and USP14, 
hydrolysis of UbAMC was measured. Proteasomes were diluted to 5 nM in 
reaction buffer, 50 mM Tris pH 7.6, 0.5 mM EDTA, 0.1% bovine serum albumin, 
and 5 mM DTT. Reactions were initiated by addition of UbAMC (Boston 
Biochem) and were measured on a Tecan fluorescence plate reader (Männedorf, 
Switzerland) with 380 nm excitation wavelength and 465 nm emission 
wavelength at 30°C for 1 hr. Progress curves were plotted in Kaleidagraph. 
 
6.2.4 Synthesis and Degradation of GFP-Titin-CyclinPY Substrate 
 In order to measure rates of degradation by the rabbit 26S, a 
polyubiquitinated proteasomal substrate was needed. In the literature, there are a 
handful of substrates, however, each is limited in scope and/or synthetic 
simplicity. We utilized a substrate developed by the Martin group at UC Berkeley, 
a GFP-tagged unstructured protein, titin, fused to cyclin, a known proteasomal 
substrate, with an engineered PY motif, a degron which signals E3 ligases for 
polyubiquitination10,11. After expression and purification from E. coli, the GFP-
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mM ATP, 1 mM DTT, and an ATP recycling system (creatine phosphokinase, 
inorganic pyrophosphate, creatine phosphate) in 50 mM HEPES pH 7.5, 50 mM 
NaCl, 10% glycerol. The reactions were run at 25 °C and were quenched with 5x 
SDS PAGE buffer. 
6.3 Results 
 
6.3.1 Impact of Deubiquitinase Inhibition on Proteasome Degradation 
 The 26S proteasome was purified from rabbit muscle tissue using the Ubl-
UIM method developed by the Goldberg group and can be seen in Fig 6.34,5. 
This method did not purify a large amount of proteasomes and retained the GST-
Ubl and His-UIM proteins despite subtraction over Ni-NTA beads. However, there 
was sufficient to study the effects of inhibition of the associated deubiquitinases, 
UCH37 and USP14, by UbVME treatment. To this end, proteasomes were 
treated with and without 1 µM UbVME for 2 hours on ice to catalytically inactivate 
the endogenous associated deubiquitinases. Then each sample was assessed 
for its deubiquitinating activity by UbAMC hydrolysis assays and for its 20S core 
particle activity using a fluorogenic peptide substrate, succinate-Leu-Leu-Val-Tyr-
AMC, or SucLLVY-AMC. Not surprisingly, in the presence or absence of UbVME, 


















































































































































degradation compared to uninhibited proteasomes, despite activity of the 20S 
core particle being unchanged in the presence of UbVME (Fig 6.4). This would 
suggest that deubiquitination by UCH37 and USP14 are coupled to degradation, 
a theory still under investigation. 
Due to this result, we were curious about the effect of simultaneous 
deubiquitinase and 20S inhibition, achieved by the addition of UbVME and the 
20S inhibitor MG132. MG132 inhibits the β5 subunit of the 20S core particle, 
thereby slowing its proteolytic activities by inhibiting one of the proteolytic 
subunits12,13. We were curious as to the contribution of UbVME in slowing 
proteasomal degradation compared to MG132, a well-characterized inhibitor. 
Incubation of the 26S with inhibitors was done on ice for 2 hours in the presence 
of either MG132 or a DMSO control, or UbVME or a buffer control. First, we 
tested 20S and deubiquitinase activity by SucLLVY-AMC and UbAMC hydrolysis 
(Fig 6.5). As expected, MG132 inhibits 20S activity but not deubiquitinating 
activity, and UbVME inhibits deubiquitinating activity but not 20S activity. 20S 
activity was slightly enhanced in the presence of UbVME, a phenomenon 
previously observed by the Goldberg group (using ubiquitin-aldehyde), but 
explained as an increase in AAA ATPase activity upstream14. Interestingly, 
MG132 seems to slightly enhance deubiquitinating activity, but is within error, 
therefore was not further investigated. These results indicate appropriate levels 





















































these samples were used to test degradation of the GFP-titin-cyclinPY-Ubn 
substrate (Fig 6.5). 
 The rates of degradation of the GFP-Ubn substrate were measured by 
running time points on SDS PAGE gels to show disappearance of the heavily 
polyubiquitinated band, which were subsequently quantified by ImageJ analysis. 
MG132 alone appears to only decrease degradation by about 25% compared to 
the uninhibited sample, which is understandable because it only inhibits one of 
the catalytic subunits of the 20S, rather than all three. UbVME alone shows a 
decrease of 50% in degradation, similar to the results shown above in Figure 6.5. 
However, the combination of MG132 and UbAMC slows degradation by >90% 
compared to the uninhibited sample. As this amount is even greater than the 
additive 75% of the two inhibitors alone, this result indicates that significant 
inhibition of degradation is occurring in a coupled deubiquitination-degradation 
mechanism. 
6.4 Further Directions 
 Investigation into the coupling of UCH37/USP14 deubiquitination and 
degradation by the 26S proteasome could prove vital to our understanding of all 
protein degradation, but especially how these deubiquitinases may be the first 
step in regulation of this cellular machine. The experiments addressed here 
indicate that deubiquitination may be coupled to degradation, however, it is 
necessary to separate out the effects of deubiquitination by Rpn11 before any 
conclusions can be made. This could be achieved by incubation of proteasomes 
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with 1,10-phenanthroline, a known inhibitor of Rpn1112,15-17. It is necessary to 
determine if deubiquitination by the cysteine protease deubiquitinases has a 
separate function from that of Rpn11 and which level of deubiquitination 
contributes most to slowing the rate of proteasomal degradation. 
 Additionally, the assays described here rely on SDS PAGE gel analysis of 
the disappearance of a band of highly polyubiquitinated GFP substrates, 
however, disappearance does not isolate deubiquitination from degradation. 
These experiments are currently being pursued by a labmate, Michael Sheedlo, 
using a T7 probe and polyubiquitinated Sic1, another proteasome substrate, to 
determine the contributions of deubiquitination vs degradation. More specific 
answers to these questions are needed before we can definitively say that 
deubiquitination by UCH37 and USP14 are indeed coupled to and a contributing 
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ABSTRACT: Ubiquitination is countered by a group of
enzymes collectively called deubiquitinases (DUBs); ∼100 of
them can be found in the human genome. One of the most
interesting aspects of these enzymes is the ability of some
members to selectively recognize specific linkage types
between ubiquitin in polyubiquitin chains and their endo
and exo specificity. The structural basis of exo-specific
deubiquitination catalyzed by a DUB is poorly understood.
UCH37, a cysteine DUB conserved from fungi to humans, is a
proteasome-associated factor that regulates the proteasome by
sequentially cleaving polyubiquitin chains from their distal ends, i.e., by exo-specific deubiquitination. In addition to the catalytic
domain, the DUB features a functionally uncharacterized UCH37-like domain (ULD), presumed to keep the enzyme in an
inhibited state in its proteasome-free form. Herein we report the crystal structure of two constructs of UCH37 from Trichinella
spiralis in complex with a ubiquitin-based suicide inhibitor, ubiquitin vinyl methyl ester (UbVME). These structures show that
the ULD makes direct contact with ubiquitin stabilizing a highly unusual intramolecular salt bridge between Lys48 and Glu51 of
ubiquitin, an interaction that would be favored only with the distal ubiquitin but not with the internal ones in a Lys48-linked
polyubiquitin chain. An inspection of 39 DUB−ubiquitin structures in the Protein Data Bank reveals the uniqueness of the salt
bridge in ubiquitin bound to UCH37, an interaction that disappears when the ULD is deleted, as revealed in the structure of the
catalytic domain alone bound to UbVME. The structural data are consistent with previously reported mutational data on the
mammalian enzyme, which, together with the fact that the ULD residues that bind to ubiquitin are conserved, points to a similar
mechanism behind the exo specificity of the human enzyme. To the best of our knowledge, these data provide the only structural
example so far of how the exo specificity of a DUB can be determined by its noncatalytic domain. Thus, our data show that,
contrary to its proposed inhibitory role, the ULD actually contributes to substrate recognition and could be a major determinant
of the proteasome-associated function of UCH37. Moreover, our structures show that the unproductively oriented catalytic
cysteine in the free enzyme is aligned correctly when ubiquitin binds, suggesting a mechanism for ubiquitin selectivity.
The ubiquitin proteasome system (UPS), present in alleukaryotes, is responsible for the majority of controlled
degradation and recycling of proteins within the cell.1−5
Polyubiquitinated, and to some extent monoubiquitinated,
proteins are recognized and degraded by the 26S proteasome, a
2.5 MDa self-compartmentalizing proteolytic complex.6−13 It is
composed of two major units: the 20S core particle (CP)
consisting of 28 subunits and the 19S regulatory particle (RP)
containing 19 subunits in yeast. The proteolytic active sites are
housed within the luminal chamber of the barrel-shaped CP,
capped on both ends by the RP, which contains ubiquitin
receptors and enzymes that prepare substrates for degradation.
Entry of substrates into the CP is regulated by the RP, primarily
by opening and closing of the substrate translocation channel.
Before the substrate is translocated into the narrow channel
leading to the lumen of the CP, it is obligatorily deubiquitinated
with the help of the RP-resident JAMM metalloprotease
Rpn1114−16 and unfolded by Rpt subunits that sit within the
base subcomplex of the RP.7,9,14 However, additional regulation
Received: March 11, 2013
Revised: April 25, 2013
Published: April 25, 2013
Article
pubs.acs.org/biochemistry
© 2013 American Chemical Society 3564 dx.doi.org/10.1021/bi4003106 | Biochemistry 2013, 52, 3564−3578
118
is performed by proteasome-associated deubiquitinating
enzymes, whose underlying mechanism is still poorly under-
stood.7,17
Attachment of ubiquitin to a lysine residue(s) on target
proteins is catalyzed by the sequential action of three enzymatic
systems: E1 (ubiquitin-activating), E2 (ubiquitin-conjugating),
and E3 (ubiquitin-ligating) enzymes.18,19 Usually, ubiquitina-
tion of a target protein results in the attachment of a
polyubiquitin chain in which successive ubiquitin moieties are
attached to one of the seven lysines, or the N-terminal amino
group of the preceding monomer, to generate a homopolymeric
structure.18,20 Polyubiquitin chains of a distinct topology are
thus generated depending on which amino group of ubiquitin is
used for chain extension (lysines 6, 11, 27, 29, 33, 48, and 63 or
the amino group of Met1). A polyubiquitin chain of a specific
topology is meant for a specific type of functional out-
come.20−25 For example, a Lys48 (K48)-linked chain usually
serves as the signal for proteasomal degradation, whereas K63
chains signal other types of functions such as endocytosis, DNA
repair, and NF-κB signaling.24,26
Ubiquitination works as a reversible post-translational
modification, like phosphorylation. Deubiquitinating enzymes,
or DUBs, can hydrolytically remove ubiquitin from protein
adducts, thereby opposing the action of ubiquitin conjugating
machinery.27−33 Consequently, DUBs have been found to play
important regulatory roles in numerous ubiquitin-dependent
cellular processes.32−35 In mechanistic terms, these enzymes
can be categorized into two main groups: cysteine proteases
and zinc metalloproteases. The zinc metalloproteases consist of
only one family, the JAB1/MPN/MOV34 metalloenzymes
(JAMMs). The cysteine proteases are further broken down into
four families based on the structure of their catalytic domain:
ubiquitin carboxyl-terminal hydrolases (UCHs), ubiquitin-
specific proteases (USPs), ovarian tumor proteases (OTUs),
and Machado-Josephin domain proteases (MJDs).32
UCH37 (also known as UCHL5) is a 37 kDa DUB of the
UCH family and is one of the two proteasome-associated
DUBs, the other being USP14 (Ubp6 in yeast), known to
regulate protein degradation by the mammalian protea-
some.36−40 These associated DUBs, along with Rpn11, a
constitutive member of the RP, conduct deubiquitination at the
proteasome. However, the activities of the three enzymes are
distinct. Rpn11 is responsible for en-bloc removal of
polyubiquitin chains prior to (or concurrent with) unfolding
and translocation of the substrate into the CP, an activity that
appears to be coupled to substrate degradation.15−17 USP14
and UCH37 on the other hand are known to have chain-
trimming functions.17,37,41 The importance of these associated
DUBs to proteasome function was revealed through
pharmacological inhibition of these enzymes. A small-molecule
inhibitor of USP14 appears to accelerate proteasomal
degradation of certain substrates, whereas UCH37 inhibition
can stall proteolysis, consistent with distinct functional roles
played by the two enzymes.42−44
UCH37 was first identified as the PA700 isopeptidase, the
cysteine DUB tightly associated with the RP, also known as
PA700.38,45,46 Like other UCH family members, it contains a
conserved catalytic triad of a cysteine, a histidine, and an
aspartate. UCH37 has a canonical UCH domain that is 45%
similar to UCHL1 and 49% similar to UCHL3, its single-
domain family members.47−50 It also has an additional C-
terminal tail domain responsible for its interaction with the
Rpn13 subunit of the RP.51−54 Proteasome-bound UCH37 is
thought to behave as an “editor”, relieving poorly ubiquitinated
substrates from degradation by sequentially dismantling their
K48-linked polyubiquitin chains from the very distal end,
removing one ubiquitin at a time.37,38,45 Such a type of chain
disassembling activity can be termed as an exo cleavage activity
in contrast to the endo activity, which leads to dismantling of
chains by cleavage between internal ubiquitins. Although it has
respectable UbAMC (ubiquitin aminomethylcoumarin) hydrol-
ysis activity in its unbound form, UCH37 has been shown to
require association with the proteasome to cleave diubiquitin
(and polyubiquitin) chains.37 Additionally, its UbAMC
hydrolysis activity is enhanced upon binding with Rpn13.37,54
Interestingly, UCH37 also associates in the nucleus with the
human Ino80 chromatin remodeling complex, where it is held
in an inactive state compared to the free enzyme.55 It thus
serves as an example of a DUB whose catalytic activity is both
positively and negatively regulated by binding to specific
protein partners, making it an attractive target for structural
studies. Crystal structures have been determined for both the
catalytic domain and full-length human UCH37;56−58 however,
the mechanism of its catalytic regulation upon binding to
associated protein factors is not known. Any mechanistic
understanding of its regulation must require structural
information about UCH37 and its catalytic domain bound to
ubiquitin, which has yet to be reported.
TsUCH37 is a recently characterized lower-organism
homologue of UCH37 from Trichinella spiralis (Ts), an
infectious helminth found nearly worldwide. TsUCH37 was
identified by White et al. by incubation of the whole-cell lysate
of Ts larvae with the HA-UbVME probe (HA, the
hemagglutinin epitope, fused with the N-terminus of ubiquitin
vinyl methyl ester), an epitope-tagged irreversible inhibitor of
cysteine DUBs.59 Its structural and functional homology with
human UCH37 was then confirmed by sequence analysis, co-
immunoprecipitation with proteasomal subunits, and UbAMC
hydrolysis assays. TsUCH37 is 45% identical to its human
homologue and was shown to pull down TsADRM1, the
corresponding Rpn13 homologue, by co-immunoprecipita-
tion.59 The sequence and functional conservation between
the Ts and human enzymes implies a similar chain-editing role
of the former at the proteasome. To understand the
mechanisms associated with UCH37, we have crystallized two
constructs of TsUCH37 bound to ubiquitin vinyl methyl ester.
The structures illuminate the mode of ubiquitin recognition in
the enzyme by revealing binding interactions with the catalytic
domain, which are conserved among UCH enzymes, and
interactions unique to UCH37, notably ubiquitin binding by
the ULD, providing further explanation of the proteasome-
associated exo-specific deubiquitination activity of the DUB.
■ MATERIALS AND METHODS
Cloning, Expression, and Purification. TsUCH37cat.
TsUCH37cat (residues 1−226) was subcloned from the full-
length construct (residues 1−309) in pET28a(+) into pGEX-
6P-1 (GE Biosciences) using BamHI and XhoI restriction sites.
The protein was expressed in Escherichia coli Rosetta cells
(Novagen) grown at 37 °C in LB medium containing 100 μg/L
ampicillin to an OD600 of 1.0 and then induced with 0.5 mM
isopropyl β-D-thiogalactoside (IPTG) at 18 °C for 16 h.
Harvested cells were resuspended in lysis buffer (1× phosphate
buffered saline and 400 mM KCl) and lysed with a French
press. The lysate was then purified on a glutathione S-
transferase (GST) column (GE Biosciences) followed by
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cleavage of the GST tag by PreScission Protease (GE
Biosciences) per the manufacturer’s instructions. It was further
purified by size exclusion chromatography on a Superdex 75
column (GE Biosciences). Intein-fused ubiquitin1−75 in pTXB1
was expressed in E. coli Rosetta cells and purified on chitin
beads (New England Biosciences). Ubiquitin vinyl methyl ester
(UbVME) was synthesized by overnight incubation of Ub1−75-
MESNa (MESNa, sodium mercaptoethanesulfonate) with
glycine vinyl methyl ester and then purified on a MonoS
cation exchange column (GE Biosciences). Glycine vinyl
methyl ester was synthesized by a modified, previously
published procedure.60 TsUCH37cat was reacted with
UbVME for 4 h, followed by purification on a MonoQ anion
exchange column (GE Biosciences) to separate any unreacted
TsUCH37cat. Selenomethionine TsUCH37cat protein (SeMet
TsUCH37cat) was grown in M9 minimal medium supple-
mented with selenomethionine, reacted with UbVME, and
purified as described above.
TsUCH37ΔC46. TsUCH37FL was subcloned previously into
pET28a(+) with an N-terminally fused His tag (Novagen).
TsUCH37FL was expressed in E. coli Rosetta cells, grown at 37
°C in LB medium containing 10 μg/L kanamycin to an OD600
of 0.8, and then induced with 0.5 mM IPTG at 18 °C for 16 h.
Harvested cells were resuspended in lysis buffer [50 mM Tris-
HCl (pH 7.6), 200 mM NaCl, and 3 mM β-mercaptoethanol]
and lysed with a French press. His-tagged TsUCH37FL was
purified by immobilized metal affinity chromatography (IMAC)
and eluted with lysis buffer including 500 mM imidazole. Eluted
proteins were further purified by size exclusion chromatography
(SEC) on a Superdex 75 column (GE Biosciences) in 50 mM
HEPES (pH 7.6) and 3 mM dithiothreitol (DTT). SDS−
PAGE on the fractions indicated a cleavage of the full-length
protein, so the construct described is actually a proteolytic
cleavage product of the full-length protein. The crystal structure
(described below) lacks density for the last 46 amino acids from
the C-terminus; therefore, this construct will hereafter be
described as TsUCH37ΔC46. Fractions containing the target
protein were pooled, concentrated, and reacted with UbVME.
UbVME was synthesized and reacted with purified
TsUCH37ΔC46 as was done with TsUCH37cat. To separate
unreacted TsUCH37ΔC46, the complex was further purified by
SEC on a Superdex 75 column (GE Biosciences).
Crystallization and Structure Determination.
TsUCH37cat−UbVME Complex. The TsUCH37cat−UbVME
complex was concentrated to 3 mg/mL in 50 mM Tris (pH
7.6), 200 mM NaCl, and 1 mM DTT. Crystals were grown in 2
days at room temperature by hanging drop vapor diffusion in 3
M ammonium sulfate and 0.1 M bicine (pH 9.0) with 2 mM L-
glutathione (mixture of oxidized and reduced) additive.
Crystals were cryoprotected in 2.5 M sodium malonate and
flash-frozen in liquid nitrogen.61 Diffraction data were collected
on a Mar300 CCD detector (Mar USA) at the 23-ID-B
beamline at Argonne National Laboratory (Argonne, IL). Data
up to 1.7 Å were collected on SeMet TsUCH37cat−UbVME
crystals at the selenium peak (0.979 Å) for SAD (single-
wavelength anomalous dispersion) phasing. Data were
processed with HKL2000.62
The initial model was obtained by Se-SAD phasing in the
Phenix AutoSol wizard.63 Its sequence was built in using the
Phenix AutoBuild wizard, as well as manual model building in
Coot.63,64 Structural refinement was conducted in Phenix using
TLS refinement (with the entire asymmetric unit taken as one
TLS group), as well as optimized weighting for stereochemical
restraints.63 The data were run through Phenix Xtriage, which
confirmed the chosen space group, C2, and did not detect
evidence of crystal twinning.63 The completeness of the
crystallographic data for the TsUCH37cat−UbVME complex
was less than ideal (see Table 2); however, this did not hinder
the determination of the structure or the generation of the
structural model presented herein and can be ascribed to poor
completeness in the highest-resolution shells.
TsUCH37ΔC46−UbVME Complex. The TsUCH37ΔC46−
UbVME complex was concentrated to 5 mg/mL in 50 mM
HEPES (pH 7.6) and 2 mM DTT. Crystals were grown in 60
days at room temperature in 0.2 M ammonium chloride (pH
5.8) and 18% PEG3350. Crystals were cryoprotected in
ethylene glycol and flash-frozen in liquid nitrogen. Diffraction
data were collected on a Mar300 CCD detector (Mar USA) at
the 23-ID-B beamline at Argonne National Laboratory. Data up
to 2.0 Å were collected on TsUCH37ΔC46−UbVME crystals at
1.033 Å. Data were processed with HKL2000.62
The initial model was obtained by molecular replacement
using the Phenix AutoMR wizard, with a monomer of the
TsUCH37cat−UbVME complex as the search model.63 Manual
model building was conducted in Coot, and structural
refinement was conducted initially in Refmac using TLS
refinement and then using simulated annealing and individual B
factor refinement in Phenix.63,64 The data were run through
Phenix Xtriage, which confirmed the chosen space group, R3,
and did not detect any evidence of crystal twinning.63
UbAMC Hydrolysis Assay. TsUCH37cat was diluted in
reaction buffer [50 mM Tris (pH 7.6), 0.5 mM EDTA, 0.1%
bovine serum albumin, and 5 mM DTT] to a final reaction
concentration of 7 nM and preincubated at 30 °C for 5 min
prior to the addition of the UbAMC substrate (Boston
Biochem). UbAMC cleavage was measured on a Tecan
(Man̈nedorf, Switzerland) fluorescence plate reader with 380
nm excitation and 465 nm emission wavelengths at 30 °C. Data
were fit to Michaelis−Menten kinetics in SigmaPlot (Systat
Software, San Jose, CA).
Analytical Ultracentrifugation. Sedimentation velocity
experiments were conducted with the Beckman-Coulter XLA
analytical ultracentrifuge. The sample was extensively dialyzed
against 50 mM Tris-HCl, 200 mM NaCl, and 1 mM DTT (pH
7.4). The TsUCH37cat and TsUCH37cat−UbVME complex
concentration ranged from 10 to 32 μM. The samples were
centrifuged at 50000 rpm using a two-sector 1.2 cm path-length
carbon-filled Epon centerpiece. The experiments were con-
ducted on an An-50 Ti rotor at 20 °C. The density and relative
viscosity of the buffers were calculated using SEDNTERP
version 1.09 (http://www.rasmb.bbri.org/rasmb/windows/
sednterp-philo): 1.0079 g/mL and 0.01036 P, respectively.
The partial specific volume (vbar) of the protein was also
calculated from the protein sequence using SEDNTERP
(0.7340 mL/g for TsUCH37cat and 0.7317 mL/g for the
TsUCH37cat−UbVME complex). The samples were monitored
at 280 nm with a 4 min delay and 150 scans. The c(s)
distributions were analyzed using SEDFIT version 13.0b.65
Molecular Dynamics Simulations. A model of full-length
TsUCH37 was generated by the SwissModel homology
modeling server using the structure of the full-length human
protein as a template.66 Missing ULD residues produced by the
model were appended to the TsUCH37ΔC46−UbVME
structure in Coot, and a single round of refinement was
conducted in Phenix, to produce a final model hereafter termed
“the system”.63,64 The system was solvated in a box of TIP3P
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water with the minimal distance between any solute atom and
the boundary of the box set to 10 Å. The system was
neutralized with 15 Na+ ions, which were automatically
positioned by the tleap program. Molecular dynamics (MD)
simulations were performed using Amber 10 with Amber force
field ff03.67 Periodic boundary conditions were applied, and the
full electrostatic energy was calculated using the particle mesh
Ewald (PME) method.68 The simulation consisted of three
sequential steps: energy minimization for 5000 steps (2500
steps of steepest-descent followed by 2500 steps of conjugate
gradient minimization), equilibration for 100 ps of solvent with
the protein restraint with a force constant of 5 kcal mol−1 Å−1,
and a final MD simulation for 2 ns. All simulations were
conducted at 300 K with a constant volume. A time step of 2 fs
was used, and the SHAKE algorithm was applied to constrain
the bonds involving hydrogen atoms.69
■ RESULTS
TsUCH37, like its mammalian counterpart, contains a catalytic
UCH domain, and an additional polypeptide chain following it
called the C-terminal tail comprising the conserved UCH37-
like domain (ULD) followed by a putative KEKE motif (Figure
1b).37,51,70,71 The ULD in human UCH37 is thought to have an
inhibitory role, presumably by folding onto the catalytic domain
thereby occluding ubiquitin binding.37 However, how ubiquitin
binds to UCH37 has not been structurally characterized. To
gain insight into how ubiquitin is recognized by TsUCH37, we
aimed to crystallize both the catalytic domain of TsUCH37
bound to ubiquitin vinyl methyl ester (UbVME) (the
TsUCH37cat−UbVME complex) and the UbVME complex of
the full-length protein. UbVME is a suicide substrate of cysteine
DUBs, which react with the former via nucleophilic attack of
the catalytic cysteine at the vinyl group of the VME moiety,
resulting in an irreversible modification whereby a covalent
bond is formed between the catalytic cysteine and the VME
portion of the inhibitor (Figure 1a).36,48,60 This covalent adduct
is thought to mimic the acyl-enzyme intermediate formed
during deubiquitination reactions catalyzed by the DUB (II and
IV in Figure 1a). If diubiquitin is used as the substrate, the
distal ubiquitin moiety is the acyl component of the acyl-
enzyme intermediate, with the proximal ubiquitin acting as the
leaving group during isopeptide bond hydrolysis (in diubiqui-
tin, a lysine residue of one ubiquitin, called the proximal
ubiquitin, is linked via an isopeptide bond to the C-terminal
carboxylate group of another ubiquitin, called the distal
ubiquitin) (III in Figure 1a).
The TsUCH37cat−UbVME complex crystallized in the C2
space group with two molecules of the complex in the
asymmetric unit. Our attempts to crystallize the full-length
version, however, were met with limited success, the full-length
protein being susceptible to proteolysis as indicated by at least
two closely migrating bands in an SDS−PAGE gel (data not
shown). While attempting to purify the full-length construct,
we managed to retrieve a truncated version of the protein
lacking 46 amino acids from the C-terminal end of the protein
(see Materials and Methods). This truncated protein was
Figure 1. (a) Schematic structures representing inhibition of UCH37 by UbVME (I and II). Definition of proximal and distal ubiquitin in a
diubiquitin substrate (III). Schematic structure of the acyl-enzyme intermediate formed during deubiquitination catalyzed by a cysteine DUB (IV).
The UbVME adduct (II) mimics the acyl-enzyme intermediate (IV), as shown in yellow. (b) Domain diagrams of TsUCH37 constructs compared to
other UCH family members with UCH domains boxed in gray and additional domains boxed and labeled as shown. (c) Kinetic assay of UbAMC
hydrolysis by TsUCH37cat. (d) Analytical ultracentrifugation profiles of TsUCH37cat (left) and the TsUCH37cat−UbVME complex (right),
indicating that both are monomeric in solution.
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purified by Ni affinity chromatography and reacted with
UbVME, and the complex was purified using ion-exchange
chromatography. This complex, hereafter termed the
TsUCH37ΔC46−UbVME complex (TsUCH37 missing the last
46 residues), crystallized in the R3 space group with one
complex in the asymmetric unit.
The catalytic activity of TsUCH37cat was measured with a
UbAMC hydrolysis assay (Figure 1c), which yielded
Michaelis−Menten parameters as shown in Table 1. Compared
to the catalytic domain of human UCH37, TsUCH37cat has an
approximately 20-fold lower KM, indicating a higher affinity for
this substrate compared to that of the human protein, but a
100-fold lower kcat, a substantially lower turnover number.
Consequently, TsUCH37cat is nearly 5-fold less efficient than
the UCH domain of human UCH37.
Crystals of the TsUCH37cat−UbVME complex diffracted to
1.7 Å. The structure was determined by single-wavelength
anomalous dispersion (SAD) using anomalous scattering from
selenium (TsUCH37cat was labeled with selenium). Manual
model building using Coot, followed by multiple rounds of
refinement using Phenix, produced a final model with an R
factor of 17.4% and an Rfree of 21% (see Table 2 for
crystallographic and refinement parameters).63,64 The final
refined model corresponding to the asymmetric unit consists of
two copies of the TsUCH37cat−UbVME complex, composed of
TsUCH37cat, residues 1−226, covalently connected via a
thioether bond linking the catalytic cysteine with the VME
group of UbVME (residues 1−75 of ubiquitin attached to
GlyVME as the 76th residue, which is modeled as methyl 4-
amino butanoate). The refined model was of high stereo-
chemical quality, with <0.2% of residues in the disallowed
region of the Ramachandran plot and scoring in the upper 98%
according to Molprobity evaluation.72 The structure of the
TsUCH37ΔC46−UbVME complex (2.0 Å resolution) was
determined by molecular replacement using the
TsUCH37cat−UbVME structure as the search model (Table
2). The final refined model with good stereochemical quality
(<0.2% of residues in the disallowed region of the
Ramachandran plot and Molprobity score of 63%) has amino
acids 5−263 of the protein and one UbVME linked via a
thioether bond to the catalytic cysteine. The structures of the
UCH domain in the two constructs are very similar, except for
two loop regions (see below), with Cα root-mean-square
deviations (rmsds) of 0.32 Å between the two (the loop regions
were excluded from the calculation of the rmsd). When
discussing the structure of the UCH domain alone or its
interaction with UbVME, we will therefore use the structure of
the TsUCH37cat−UbVME complex because its resolution is
higher while specifically mentioning any structural feature that
is different in the UCH domain of TsUCH37ΔC46−UbVME
complex.
Initial analysis of the structure revealed that the two copies in
the asymmetric unit of TsUCH37cat−UbVME crystals are
linked by a disulfide bond between Cys71 of the two
TsUCH37cat chains (Figure 2a). It is possible that the disulfide
bond forms because the protein exists as a dimer in solution,
bringing the cysteines into proximity of each other, or is a result
of crystallographic packing. To determine if this disulfide is a
crystallographic artifact or a biologically relevant association, we
determined the oligomerization state of complexed and
uncomplexed (apo) TsUCH37cat by sedimentation velocity
analytical ultracentrifugation (AUC). We found that both the
complex and the apo protein exist as monomers in solution
with sedimentation coefficients (S20,w) of 3.3 and 2.8,
respectively (Figure 1d), indicating that this disulfide is likely
a result of crystal packing. TsUCH37 is expected to be
predominantly localized to the cytosol, a reducing environment,
and therefore should not rely on disulfide-mediated dimeriza-
tion for catalytic activity. Moreover, the observation that the
Table 1. Kinetic Parameters for TsUCH37cat
enzyme KM (nM) kcat (s
−1) kcat/KM (×10
5 M−1 s−1)
TsUCH37cat 1085 0.37 3.4
UCH37N240a 21493 34 16
UCHL3a 77.1 19 2414
UCHL1a 47.0 0.03 7.4
aKinetic parameters previously determined, from ref 75.






space group C121 R3
cell dimensions
a, b, c (Å) 171.2, 55.8, 73.9 147.4, 147.4, 40.5
α, β, γ (deg) 90, 113.4, 90 90, 90, 120
wavelength (Å) 0.979 1.033
resolution (Å) 50.00−1.70 (1.73−1.70) 50−2.0 (2.03−2.00)
Rsym or Rmerge
b (%) 8.7 (50.0) 8.5 (83.8)
I/σI 15.9 (3.0) 4.9 (4.1)
completeness (%) 88.5 (42.0) 100.0 (100.0)
redundancy 6.8 (3.5) 5.8 (5.7)
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aNumbers in parentheses refer to data in the highest-resolution shell.
bRmerge = ∑|Ih − ⟨Ih⟩|/∑Ih, where Ih is the observed intensity and ⟨Ih⟩
is the average intensity. cRwork = ∑||Fobs| − k|Fcal||/∑|Fobs|. dRfree is the
same as Robs for a selected subset (5 and 9%) of the reflections that
was not included in prior refinement calculations. eOrdered residues:
Pro3−Gly141 and Lys153−Asp224 in chain C and Pro3−Gly141 and
Gln152−Gln225 in chain A of the SeMet TsUCH37cat−UbVME
structure and Gly4−Lys57, Thr72−Gly141, and Glu157−Ala263 of
the TsUCH37ΔC46−UbVME structure.
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TsUCH37ΔC46−UbVME complex is a monomer in the
asymmetric unit and that the segment of residues 57−71,
which is used as a part of the dimer interface in the crystals of
the TsUCH37cat−UbVME complex, is disordered in the
TsUCH37ΔC46−UbVME structure (Figures 2 and 3) supports
the notion that the dimer observed in the TsUCH37cat−
UbVME structure is a crystallographic dimer and may not exist
in solution. The two copies of the complex in the dimer
observed in the crystals of the TsUCH37cat−UbVME complex
have very similar structures with an rmsd of 0.39 Å between Cα
atoms. We will therefore focus on one of them in discussions
presented below.
Overall Structure of the UCH Domain of TsUCH37.
The overall structure of the TsUCH37 catalytic domain is
similar to that of other structurally characterized UCH
enzymes.49,50,73 It has the classical αβα fold, in which a central
six-stranded β-sheet is surrounded by six α-helices, five on one
side (α1−α5) and one on the other (α6) (Figure 3). The
overall architecture of TsUCH37cat can be seen as bilobal, with
one of the lobes comprising helices α1−α5 and the other
comprising the β-sheets and helix α6. The active site is located
at the interface of the two lobes, with Cys85 from helix α2 in
one lobe and His161 from β3 in the other forming the catalytic
Cys-His pair. An adjacent loop provides the third member of
the triad, Asp176. Most of the secondary structural elements
seen in TsUCH37cat are conserved in UCHL1 and UCHL3,
with the only noticeable difference being the conformation of a
segment following β2, residues 57−71. This segment is a helix
in UCHL1 and UCHL3 and is in somewhat of an extended
looplike conformation in human UCH37 (hUCH37) but is
fairly ordered; in the structure of the various constructs of
human UCH37 determined so far, this loop has been found to
be in a similar conformation regardless of crystallographic
packing (Figure S1 of the Supporting Information).56−58,74 In
contrast, this segment appears to be flexible in TsUCH37 and is
visualized only in the TsUCH37cat−UbVME structure, in which
it forms the dimer interface between the two subunits in the
asymmetric unit. In the TsUCH37ΔC46−UbVME complex, a
crystallographic monomer, this loop is disordered (Figure 3).
Although the possibility that its binding can influence the loop
dynamics cannot be ruled out, it is unlikely that UbVME has
anything to do with the dynamic behavior of the loop because it
does not bind to it. We therefore propose that the loop is
intrinsically flexible in TsUCH37 but can become ordered
under certain circumstances, such as under the constraints of
crystallographic packing.
It is possible that the corresponding loop segment in
hUCH37 is somewhat dynamic as well, but it appears to be
significantly more flexible in TsUCH37. The significance of this
difference in dynamics between the two proteins is not clear at
the moment. Intriguingly, the loop’s dynamic behavior appears
to have an effect on the conformation of a tryptophan residue
(Trp55) adjacent to the active site (Figure S2 of the Supporting
Information). This tryptophan is conserved among Schizo-
saccharomyces pombe (Sp), Ts, and human UCH37 (Figure S3
Figure 2. Crystal structures of TsUCH37 constructs bound to UbVME. (a) Dimeric structure of TsUCH37cat bound to UbVME (orange) in
crystals. Monomers are colored teal (chain A) and gray (chain C). The inset shows the disulfide bridge that links the two subunits via Cys71. The
electron density is rendered from the 2Fo − Fc map contoured at 1σ. (b) Monomer of the TsUCH37cat−UbVME structure. (c) Structure of the
TsUCH37ΔC46−UbVME complex, with TsUCH37ΔC46 colored olive and UbVME orange.
Figure 3. Secondary structures of TsUCH37 constructs.
TsUCH37ΔC46−UbVME and TsUCH37cat−UbVME complexes are
superposed with α-helices and 310-helices colored pale yellow, β-sheets
blue, loops green, and UbVME orange. Arrows indicate where the
TsUCH37ΔC46−UbVME structure lacks density, compared to the
TsUCH37cat−UbVME structure, from residue 57 to 71.
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of the Supporting Information). In the TsUCH37ΔC46−
UbVME complex, Trp55 makes contact with the OMe group
of the suicide inhibitor, which in the actual substrate (a
ubiquitinated protein or the diubiquitin motif of a polyubiquitin
chain) would be replaced by the hydrocarbon portion of the
isopeptide-linked lysine side chain (Figure 1a). The same
residue in the TsUCH37cat−UbVME complex shows a different
orientation with respect to the OMe group and appears to have
adopted a more open position for interaction with the
isopeptide unit (Figure S2 of the Supporting Information).
Therefore, Trp55 not only may provide important contacts
with the isopeptide link to hold it in place near the active site
but also may confer a certain plasticity to the active site of
UCH37, which may be useful for an induced-fit type of
engagement with the substrate.
As stated before, in the TsUCH37ΔC46−UbVME structure,
we are able to visualize 40 additional amino acids after the
UCH domain, the first 41 amino acids (residues 223−263) of
the ULD in TsUCH37. The polypeptide chain, after emerging
from the C-terminus of the UCH domain, adopts a helical
structure of six turns (α7), takes a U-turn, and then continues
as a helix (α8). α7 and α8 are arranged as a helix−turn−helix
motif with a number of interhelical contacts, and this motif
adopts a similar orientation with respect to the UCH domain as
observed in hUCH37 (Figures 3 and 4b).57 The only difference
in this motif between TsUCH37 and hUCH37 is that it is
somewhat shorter in the former. The ULD in TsUCH37
appears to have a proteolytically susceptible region after
Ala263, perhaps immediately following it, producing the C-
terminal truncation we are observing here. When we model the
missing part of the ULD, using the structure of hUCH37 as a
template (see Materials and Methods), it is apparent that α8
could have continued on after the cleavage site (Figure 4b)
almost as a long helix all the way up to residue 285, except for
an interruption at Arg268 where four successive residues,
including the arginine, adopt nonhelical dihedral angles
producing a kink (a kink featuring equivalent residues is also
seen in the template structure). As expected from the hUCH37
structure, the model shows that after the interruption, the helix
would terminate at or near amino acid 285 (Figure 4), where
the polypeptide chain reverses its direction as a turn segment
that appears to cap the C-terminus of the helix. The putative
KEKE motif was not modeled because it is absent in the
template structure. Interestingly, the structure of the
TsUCH37ΔC46−UbVME complex reveals side chains from α8
making contact with ubiquitin, specifically with its Lys48
residue, an interaction that may explain the distal end specificity
displayed by UCH37 (discussed in more detail below). Also,
the side chains from the modeled part of the ULD, missing in
our structure, appear to present themselves for additional
contacts with ubiquitin. Indeed, the two most conserved
residues in the ULD, Glu265 and Asn272, are facing ubiquitin
and lie within contact distances (Figure 4c). Thus, it is possible
that they may actually bind to ubiquitin. Alternatively, in
contrast to what is predicted by the model, these residues may
be used for making contact with Rpn13, explaining why they
are conserved.
Active-Site Geometry. The catalytic triad in this cysteine
protease assumes a canonical arrangement in the ubiquitin-
bound complex. The distance between the catalytic cysteine
and histidine is 3.9 Å (Nδ−Sγ distance) in both structures, and
that between the histidine and aspartate is 2.8 Å (Nε−Oδ) in
the TsUCH37cat−UbVME complex and 2.9 Å in the
TsUCH37ΔC46−UbVME complex. The distance between the
CεH group of the catalytic histidine and the side chain carbonyl
oxygen of the oxyanion stabilizing glutamine (Gln79) is 3.3 Å
in the TsUCH37cat−UbVME complex and 3.1 Å in the
TsUCH37ΔC46−UbVME complex, suggesting a significant
CH···O interaction between them, an interaction seen in
other cysteine proteases as well.75 We were unable to crystallize
Figure 4. ULD−ubiquitin interactions. (a) Sequence alignment of the ULD of UCH37 highlighting conserved residues in UCH37 homologues.
Glu265 and Asn272 (according to Ts numbering) are absolutely conserved (highlighted in red). (b) Superposition of the TsUCH37ΔC46−UbVME
complex (ULD colored olive and UbVME orange), human UCH37 (ULD colored purple, PDB entry 3IHR), and TsUCH37 with the entire ULD
modeled (cyan) based on the structure of the ULD in human UCH37. The model was generated using SwissModel and MD simulation (please see
Materials and Methods). This model is taken from a snapshot collected at 1.3 ns during a 2 ns MD simulation run. (c) Structure of the TsUCH37−
ubiquitin complex with the entire ULD modeled as shown in panel b, showing that the conserved residues of the ULD could make additional
contacts with ubiquitin. The regions marked i and ii are expanded in the panels below. The UCH domain is colored gray.
Biochemistry Article
dx.doi.org/10.1021/bi4003106 | Biochemistry 2013, 52, 3564−35783570
124
the apo form of either TsUCH37cat or TsUCH37ΔC46. In its
place, we use the structure of apo human UCH37 to gain
insight into structural changes in the active-site region that may
occur upon ubiquitin binding.57,58 Comparison with the
structures of human UCH37 reveals that the catalytic cysteine
has changed its orientation, going from the apo form to the
ubiquitin-bound form, adopting a more productive orientation
in the latter, an orientation in which the catalytic cysteine’s side
chain faces the catalytic cleft (Figure 5g). This analysis suggests
that UCH37 exists in an unproductive form in the absence of
ubiquitin, with the catalytic thiol facing the interior of the
protein rather than the open space in the catalytic cleft,58 but is
induced to adopt a more productive form upon its binding.
Thus, UCH37 may offer yet another example of a UCH DUB
that undergoes substrate-induced reorganization to a more
productive form.48,76
Crossover Loop Flexibility. A common structural feature
present in all UCH enzymes is the crossover loop, which in
TsUCH37 spans residues 141−157 (connecting α5 with β3). It
straddles the active-site cleft as a flexible loop and is known to
Figure 5. Recognition of ubiquitin by TsUCH37. (a) Surface rendering of TsUCH37cat (cyan) with ubiquitin binding regions highlighted. The distal
site is colored yellow and the active-site cysteine red, and resolved portions of the crossover loop are colored pink. (b) Surface rendering of
TsUCH37ΔC46 (green) with ubiquitin binding regions highlighted as in panel a, except with additional C-terminal tail ubiquitin binding residues
colored blue. (c) Interactions near the active-site cleft with the C-terminal hexapeptide tail of ubiquitin. UbVME residues are colored orange,
TsUCH37 residues teal, and human UCH37 residues purple. (d) Interactions of Arg72 of ubiquitin with surrounding residues of TsUCH37cat.
Density from the 2Fo − Fc map is contoured at 1σ (blue mesh). (e) UCH37 distal-site binding residues, with TsUCH37 colored teal and human
UCH37 purple. (f) Ile44 patch interacting residues, with UbVME colored orange, TsUCH37 teal, and human UCH37 purple. Waters involved in
binding are also shown, enveloped with density from the 2Fo − Fc map contoured at 1σ. Sequence alignment of this region in TsUCH37 compared
to human UCH37 is shown as an inset. (g) Active site of TsUCH37 (teal), showing the catalytic residues, compared to human UCH37 (purple),
with UbVME colored orange.
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provide steric constraint, limiting the size of the leaving group
at the C-terminus of ubiquitin.74,77 Accordingly, UCH enzymes,
such as UCHL1 and UCHL3, can cleave only small leaving
groups from the C-terminus of ubiquitin, not large proteins or
another ubiquitin.47 However, UCH37 is known to cleave
diubiquitin (and polyubiquitin chains), but only when it is
associated with the RP, being activated upon binding to its
protein cofactor, Rpn13.37 All previously determined structures
of UCH enzymes bound to ubiquitin have shown a resolved
crossover loop, which makes contact with at least one residue
from the C-terminal tail of ubiquitin. In the apo form of
UCHL3, the closest homologue of UCH37, the loop is
disordered but becomes ordered when ubiquitin is bound.48,50
The ubiquitin-bound structures of PfUCHL3 and the yeast
ubiquitin hydrolase Yuh1 show an ordered crossover loop
making contacts with side chains on the C-terminal tail of
ubiquitin.73,78 In contrast, the structures of the TsUCH37−
UbVME constructs present the only examples so far of a UCH
DUB in which the crossover loop is still disordered even after
ubiquitin is bound, indicating that the loop is flexible and does
not contribute to ubiquitin binding. A small network of van der
Waals interactions and hydrogen bonds seem to stabilize part of
the crossover loop (residues 152−157) in a short helical
conformation in the structure of the TsUCH37cat−UbVME
complex, but the same segment in the TsUCH37ΔC46−UbVME
structure is disordered and hence not visible, supporting
dynamic sampling of conformations by this loop. The
observation that the crossover loop is flexible despite the
bound ubiquitin may be related to its activation by its
proteasome cofactor Rpn13.37 By not engaging with ubiquitin,
the loop is available to freely interact with the cofactor, which
may stabilize it in a conformation that leaves the active site
maximally open to accommodate the isopeptide bond between
two ubiquitins or between ubiquitin and an acceptor protein.
Interactions with Ubiquitin. The interaction of UbVME
with the TsUCH37cat UCH domain buries a total of 2355 Å2 of
solvent accessible surface area, a value comparable to the
amount buried in other UCH domain ubiquitin complexes (the
buried accessible surface area in the TsUCH37ΔC46−UbVME
complex is 2479 Å2).48,76 The interaction is predominantly
localized at two areas on TsUCH37, the active-site cleft and the
distal site (Figure 5a,b) The active-site cleft engages the C-
terminal hexapeptide segment, Leu71ArgLeuArgGly-Gly76VME,
of UbVME with numerous intermolecular contacts that include
van der Waals, hydrogen bonding, electrostatic, and water-
mediated interactions (Figure 5c). This segment sits in the
active-site cleft with an extended conformation to maximize
interactions with both backbone and side chain atoms of nearby
residues of the enzyme. As seen in other UCH structures, the
narrowest part of the active-site cleft surrounds the terminal
Gly-Gly motif, with the last Gly (GlyVME in this case) being
placed immediately adjacent to the Sγ atom of the catalytic
cysteine, precisely located for nucleophilic attack on the scissile
peptide bond (Figure 5a,b). It is interesting to note that Arg72
of UbVME is engaged in at least three major interactions
(Figure 5d), suggesting that it contributes significantly to
stabilizing the enzyme−substrate complex. The interactions
with Arg72 imply that TsUCH37 will find NEDD8 (neural
precursor cell expressed, developmentally downregulated 8, a
structurally similar ubiquitin-like protein modifier with a
sequence that is 60% identical with that of ubiquitin) as a
poorer substrate because this arginine is replaced with alanine
in NEDD8. Indeed, TsUCH37 does not cleave NEDD8-AMC
(see Figure S4 of the Supporting Information). Many of the
active-site interactions observed in the ubiquitin-bound
structures of UCHL1, UCHL3, PfUCHL3, and Yuh1 are
conserved in both TsUCH37 structures. Additionally, those
residues surrounding the C-terminal hexapeptide tail of
ubiquitin are strongly conserved between the Ts and human
protein (Figure 5c).
The interactions at the active-site cleft appear to be necessary
for precise cleavage at the terminal glycine residue of ubiquitin,
while the distal site provides additional interaction to stabilize
the enzyme−substrate complex (Figure 5e,f). The distal site
engages the N-terminal β-hairpin of ubiquitin, which docks by
utilizing interactions primarily involving the two-residue β-turn
segment, Leu8 and Thr9 of ubiquitin. These interactions are
mostly hydrophobic in nature, involving van der Waals contact
of Leu8 and Thr9 with Val35, Leu36, Ile206, Phe216, and
Leu218, residues that constitute the surface-exposed hydro-
phobic crevice that is the distal site. Leu36, Ile206, Phe216, and
Leu218 are conserved among Sp, Ts, Pf, and human UCH37
(Figure S3 of the Supporting Information), suggesting the
importance of distal-site binding in enzyme−substrate recog-
nition.
Ile44 of ubiquitin, a residue widely used in recognition by
ubiquitin-binding proteins, including DUBs, is seen making van
der Waals contacts with Val34 on a greasy loop in TsUCH37,
residues 34−36 (residues Val35 and Leu36 extend into the
distal-site pocket) (Figure 5f). A similar motif is used in other
UCH enzymes to bind to Ile44 of ubiquitin. Val34 of
TsUCH37 also makes contacts with His68 and Val70, which,
together with Ile44 and Leu8 from the N-terminal β-hairpin
turn, form the so-called Ile44 patch on ubiquitin. Thus, the
binding potential of the Ile44 patch on ubiquitin appears to be
fully satisfied in structures of the two complexes presented here,
with each residue in the patch making at least one contact with
the enzyme. The structural data presented here are supported
by previously reported mutational analysis of the PA700
isopeptidase. Replacing Ile44 and Leu8 from the Ile44 patch
with alanine in the distal ubiquitin of a diubiquitin substrate
results in significantly impaired catalysis with no detectable
hydrolysis product.45 Val34 and Val35 are replaced with
tryptophan and serine, respectively, going from Ts to human
UCH37 (Figure 5f) (Val34 provides additional contacts with
Val70 of UbVME). These residues also show variability among
other UCH family members. Subtle differences in the Ile44
patch-binding residues could be one of the contributing factors
in the difference in KM between human and Ts UCH37,
especially as most of the residues at the active site are conserved
between the two.
There appear to be no striking conformational changes
between the ubiquitin-bound form of TsUCH37 and apo
hUCH37 except for the aforementioned reorientation of the
catalytic cysteine. However, we cannot rule out the possibility
that significant conformational changes might have occurred as
a result of ubiquitin binding in the Ts enzyme because we could
not crystallize its apo form.
Ubiquitin Binding by the ULD. As mentioned earlier, the
ULD of hUCH37 was thought to have an inhibitory role,
presumably by folding onto the catalytic domain and
obstructing substrate binding.37 In contrast, the structure of
the TsUCH37ΔC46−UbVME complex provides crystallographic
evidence that the ULD can actually contribute to ubiquitin
binding and therefore can play a productive role in catalysis.
Arg261 and Tyr262 on α8 of the ULD approach ubiquitin to
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engage in van der Waals contact with of three of its side chains,
Lys48 (with Arg261) and Gln49 and Arg72 (both with Tyr262)
(Figure 6). Most notably, Arg261 is oriented in such a way to
engage in close van der Waals contact with the hydrocarbon
portion of the Lys48 side chain, forcing it to adopt an unusual
conformation that allows an intramolecular salt bridge
interaction with Glu51. This interaction is not observed in
any of the 39 other ubiquitin-bound DUB structures currently
found in the PDB, catalogued in Table 3; the Lys48−Glu51
distance is greater than 5.8 Å in all. Figure 6b shows the
orientation of the same lysine in the TsUCH37cat−UbVME
complex. Clearly, the orientation is different in this structure,
and the intramolecular salt bridge in ubiquitin is absent,
suggesting that Arg261 of the ULD plays a role in inducing the
unusual orientation of Lys48 of ubiquitin. Arg261 is conserved
among Sp, Ts, and human UCH37 (Figure 7) but is replaced
with leucine in PfUCH37 (also known as PfUCH54). Tyr262 is
conserved in human and Ts forms but is substituted with
tryptophan in Sp and PfUCH37. Inspection of the structure
reveals that the van der Waals contact with Lys48 is still feasible
with leucine in place of arginine and tryptophan can
conservatively replace tyrosine as well. Thus, it is likely that
ULD binding with Lys48 and subsequent formation of the
intramolecular salt bridge we are observing here are conserved
features of UCH37 in general.
UCH37, as a part of PA700, is known to selectively cleave
polyubiquitin chains from the very distal end, sequentially
removing one ubiquitin at a time.38 The structural basis of this
exo cleavage specificity is not yet known. The unique
orientation of Lys48 stabilized by Arg261 leading to the
intramolecular salt bridge may explain this selectivity. We
propose that although a similar type of interaction between
Arg261 and ubiquitin’s Lys48 is possible with an internal
ubiquitin, the intramolecular salt bridge will be absent in this
case because the amino group of the lysine is acylated and
hence not charged. Thus, it is the lack of an additional
interaction with an internal ubiquitin that makes binding to
Lys48 of the terminal ubiquitin more favored, hence the exo
selectivity.
■ DISCUSSION
UCH37 is a proteasome-associated UCH DUB known to have
polyubiquitin chain-editing function. It preferentially cleaves
the chain from its very distal tip.38 Such a function might rescue
Figure 6. ULD of TsUCH37 binding to ubiquitin. (a) TsUCH37ΔC46 (olive) ULD residues interacting with UbVME (orange). The inset shows
interactions of Arg261 and Tyr262 with UbVME, as well as the intramolecular salt bridge formed between Lys48 and Glu51 of ubiquitin. Density
rendered from the 2Fo − Fc map contoured to 0.7σ. (b−e) Comparison of the Lys48−Glu51 distances in ubiquitin observed in other DUB−
ubiquitin structures. (b) Lys48 and Glu51 form a 3.7 Å salt bridge in the TsUCH37ΔC46−UbVME structure (olive), but not in the TsUCH37cat−
UbVME structure (9.9 Å). (c) The same distance in all other UCH−ubiquitin structures is ≥9 Å: UCHL3−UbVME (yellow, PDB entry 1XD3),
UCHL1−UbVME (red, PDB entry 3KW5), Yuh1−Ubal (pink, PDB entry 1CMX), PfUCHL3−UbVME (purple, PDB entry 2WDT), and
TsUCH37cat−UbVME (teal). (d) The same distance is 8.7 Å in the Otu1−ubiquitin structure (dark red, PDB entry 3BY4) and 6.0 Å in the DUBA−
Ubal structure (pale yellow, PDB entry 3TMP). (e) The same distance is 10 Å in the HAUSP/USP7−Ubal structure (blue, PDB entry 1NBF) and
10.9 Å in the USP14−Ubal structure (brown, PDB entry 2AYO).
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certain substrates from being committed to further downstream
action of the proteasome.38 It is also possible that certain
substrates carry inappropriate polyubiquitin tags that are not
optimal for their degradation. The chain-editing function might
be essential for releasing these substrates to clear up ubiquitin
receptors for binding to productive substrates. A regulator of
proteasome function, it is itself regulated by binding to the
proteasome: UCH37 is activated upon binding to Rpn13, a
subunit of PA700 (the 19S proteasome or RP), the mechanism
of which is not understood. We report here the structure of two
constructs of UCH37 from the infectious helminth T. spiralis
(Ts) bound to the suicide inhibitor UbVME. This work
constitutes the first structural analysis of a ubiquitin pathway
protein in the organism showing how ubiquitin is recognized by
this UCH family DUB in Ts. The structures reveal striking
conservation of the ubiquitin binding mode among UCH
DUBs, from lower eukaryotes to human (Figure S5 of the
Supporting Information). It also shows important structural
differences between other UCH DUBs, such as UCHL1 and
UCHL3, some of which could be used for the specialized
function of UCH37. While revealing interesting differences, the
Ts structures provide a number of details that may also hold
true for the human enzyme, advancing our understanding of
UCH37 in general.
The active-site cysteine may undergo ubiquitin-mediated
reorientation to a more productive form (Figure 5g), making
UCH37 yet another example of a UCH DUB that shows
regulation of activity by ubiquitin, a feature that may provide
selectivity to this group of cysteine proteases. Structures of the
two constructs reveal invariant parts of the enzyme, likely less
dynamic parts, while also revealing parts that are more dynamic
in nature, such as the segment of residues 57−71 and Trp55.
Future studies should reveal the role of such dynamic parts in
catalysis or regulation thereof.
Importantly, the structure of the construct with the
additional 40 amino acids after the UCH domain reveals that
the ULD could contribute to ubiquitin binding (Figures 4 and
6), an unexpected finding because it was thought to be
inhibitory in the human enzyme.37 The interaction of Arg261
on the ULD appears to engage Lys48 of the distal ubiquitin in a
way that would be energetically most favored with the very
terminal ubiquitin in a polyubiquitin chain, possibly explaining
the exo specificity displayed by mammalian UCH37. These
structural data are consistent with previously reported muta-
tional analysis probing substrate specificity of the PA700
isopeptidase: mutation of Lys48 to cysteine on the distal
ubiquitin of a diubiquitin substrate results in severely impaired
catalysis.45 Apart from the broad agreement with the
aforementioned experimental work, this observation of the
intramolecular Lys48−Glu51 salt bridge in the distal ubiquitin,
apparently induced by Arg261, is purely crystallographic at this
point, although it seems unlikely that lattice forces have
anything to do with it. Even if the opposite is true, the fact that
such interactions are physiologically relevant cannot be ignored.
The lack of an intramolecular Lys48−Glu51 salt bridge in any
other ubiquitin-bound DUB structures to date (Table 3) makes
this unusual interaction more intriguing, and worth additional
study. This observation therefore lays the structural ground-
work for future mutational analysis aimed at validating their
existence in solution and their role in substrate specificity.
It is interesting to note that a salt bridge interaction, albeit an
intermolecular one, involving Lys48 of ubiquitin and an acidic
side chain of the enzyme is also seen in the structure of USP7
bound to ubiquitin aldehyde (the Lys48 side chain of the distal
ubiquitin is interacting with Asp305 and Glu308 of USP7).79
Such bifurcated salt bridges will perhaps contribute substan-
tially to the binding of the enzyme to distal ubiquitin in a K48-
linked chain, based on which one may predict that USP7 will
also exhibit exo specificity. This needs to be examined.
Preferential cleavage from the very distal tip of a Lys48-linked
polyubiquitin chain may be a feature common to DUBs that
work on chains of this topology. Lys48-linked chains are known







1XD3 UCHL3−UbVME 9.1, 11.5
1CMX YUH1−Ubal 10.8
2WDT PfUCHL3−UbVME 7.3, 9.6
3IFW UCHL1 S18Y−UbVME 8.7




2Y5B USP21−linear diUbal 7.8, 10.8, 6.6
1NBF HAUSP−Ubal 10.0, 10.7
2AYO USP14−Ubal 10.9
3MHS SAGA complex (UBP8)−Ubal 9.2
2HD5 USP2, Ub 9.0
2G45 IsoT, Ub 8.6, 8.9
2J7Q M48 USP−UbVME 9.9, 10.8
3V6E USP2, Ub variant 7.0
3V6C USP2, Ub variant 7.4
3IHP USP5, Ub covalent 9.6, 6.3
3MTN USP21, ubiquitin-based USP21-specific
inhibitor
8.5
3IT3 USP21, Ub covalent 7.4, 7.5, 7.4, 7.4
3N3K USP8, covalent Ub-like variant 10.4
3NHE USP2a, Ub 7.4
2IBI USP2, Ub covalent 7.6
OTU Family
4IUM arterivirus papain-like protease 2, Ub 7.4
3ZNH CCHF viral, Ub-propargyl 9.5
4I6L OTUB1, Ub 9.1
3PT2 viral OTU, Ub 10.7
4HXD Nairovirus viral OTU, Ub 8.3, 10.1
3BY4 OTU, Ub 6.0
3PRM CCHF viral OTU, Ub 9.5, 10.0
3PRP CCHF viral OTU, Ub 10.3, 10.9




4DHJ ceOTUB1 ubiquitin aldehyde
UBC13∼Ub complex
11.4, 8.5, 6.9, 11.8, 9.8,
10.1
4DDI OTUB1/UbcH5b∼Ub/Ub 7.5, 12.6, 12.6, 7.5,
12.6, 7.5
4DDG OTUB1/UbcH5b∼Ub/Ub 11.3, 7.1, 8.0
3PHW OTU domain of CCHF virus, Ub 7.6, 7.2, 9.0, 5.8
MJD Family
3O65 Ataxin-3-like, Ub 9.6, 11.4, 12.8, 11.5
2JRI Ataxin 3, Ub 12.3, 12.9
JAMM Family
2ZNV AMSH-LP, Lys63-linked diubiquitin 9.0, 8.3, 11.9, 11.3
aMultiple distance entries refer to those in the other subunits of the
crystallographic asymmetric unit.
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to adopt a compact structure.80 However, the terminal
ubiquitin, being less packed than the internal ones (packed
from both sides), is more likely to fray and be susceptible to
DUB cleavage for stereochemical reasons. Certain DUBs may
have evolved a mechanism for grabbing onto those fraying ends
and start disassembling chains from there. There may be other
DUBs that prefer internal ubiquitins, or the terminal ones on
the other extreme end of the chain, such as isopeptidase-T
(USP5),81 and there may be some with no preference at all.
The structure of AMSH-LP (a Lys63-linked chain-specific
DUB) in complex with Lys63-linked diubiquitin shows that
Lys63 on the distal ubiquitin is not engaged by the enzyme,
suggesting it is unlikely to show any preference between the
terminal and internal cleavage sites.82 This is consistent with
the structure of a Lys63-linked chain, which adopts a more
extended conformation in crystals and perhaps in solution as
well.83−85 Future structural studies should reveal more details
explaining exo and endo specificity seen in certain DUBs.
The structural analysis, combined with MD simulation,
shows the contribution of the ULD in ubiquitin binding. In
theory, certain residues in TsUCH37’s ULD, missing in our
structure, also appear to be correctly positioned for contacting
ubiquitin. Notably, the modeling study provides a possible
explanation of why Glu265 and Asn272 are so strictly
conserved in UCH37 from different organisms, with virtually
no exception. Contributing to ubiquitin binding, as suggested
by our modeling studies, may be one of the functional
constraints underlying the conservation of the amino acids,
although one cannot rule out whether binding to other proteins
such as Rpn13 may be involved. It should be noted that Bap1, a
UCH DUB mutated in several cancers, also features a
ULD.70,71,86 Like UCH37, Bap1 becomes activated upon
binding to a larger protein complex, demonstrated with the
Drosophila orthologue, Calypso, binding to the polycomb
repressor DUB complex.87 Interestingly, the putative ubiquitin-
binding residues of the ULD of UCH37 are also conserved in
Bap1 (data not shown), suggesting a role in ubiquitin binding
for Bap1’s ULD as well (in some Bap1 orthologues, the
glutamate corresponding to TsUCH37’s Glu265 is replaced
with an aspartate). However, human Bap1 has a linker of
approximately 300 amino acids separating the UCH domain
and its ULD. It will be interesting to see how the ULD
positions itself to bind ubiquitin, if it does. Of more interest is
Figure 7. Sequence alignment of TsUCH37 and other homologues: human UCH37, S. pombe Uch2, and Plasmodium falciparum UCH54. Secondary
structures for the two TsUCH37 structures are annotated above (e.g., α1, α-helix 1; β1, β-sheet 1; η1, 310-helix 1). α2′ and η2 are not resolved in the
TsUCH37ΔC46−UbVME structure, and helices α7 and α8 are not present in the TsUCH37cat−UbVME construct.
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Supporting figures and NEDD8 hydrolysis data (Figure S4).
This material is available free of charge via the Internet at
http://pubs.acs.org.
Accession Codes
Coordinates and structure factors have been deposited in the
Protein Data Bank as entries 4I6N and 4IG7.
■ AUTHOR INFORMATION
Corresponding Author
*Brown Laboratory of Chemistry, 560 Oval Dr., West
Lafayette, IN 47907. E-mail: cdas@purdue.edu. Phone: (765)
494-5478. Fax: (765) 494-0239.
Author Contributions
M.E.M. and M.-I.K. contributed equally to this work.
Funding
Financial support from the National Institutes of Health
(1R01RR026273, C.D.) is gratefully acknowledged. The
General Medicine and Cancer Institutes Collaborative Access
Team (GM/CA CAT) of the Advanced Photon Source at
Argonne National Laboratory has been funded in whole or in
part with Federal funds from the National Cancer Institute (Y1-
CO-1020) and the National Institute of General Medical
Sciences (Y1-GM-1104).
Notes
The authors declare no competing financial interest.
■ ACKNOWLEDGMENTS
We acknowledge Venugopalan Nagarajan, Ruslan Sanishvili,
and Craig Ogata at beamline 23-ID-B of the Advanced Photon
Source for assistance with data collection. Use of the Advanced
Photon Source was supported by the U.S. Department of
Energy, Basic Energy Sciences, Office of Science, under
Contract DE-AC02-06CH11357. We thank Emma DeWalt
and Garth Simpson from the Department of Chemistry, Purdue
University, for their assistance with SONICC imaging of initial
crystals.
■ ABBREVIATIONS
SDS−PAGE, sodium dodecyl sulfate−polyacrylamide gel
electrophoresis; DTT, dithiothreitol; IPTG, isopropyl β-D-1-
thiogalactopyranoside; UbVME, ubiquitin vinyl methyl ester;
UbAMC, ubiquitin aminomethylcoumarin; UCH37, ubiquitin
carboxyl-terminal hydrolase 37; DUB, deubiquitinating enzyme
or deubiquitinase; PDB, Protein Data Bank.
■ REFERENCES
(1) Ciechanover, A. (2005) Proteolysis: From the lysosome to
ubiquitin and the proteasome. Nat. Rev. Mol. Cell Biol. 6, 79−87.
(2) Ciechanover, A., and Schwartz, A. L. (2002) Ubiquitin-mediated
degradation of cellular proteins in health and disease. Hepatology 35,
3−6.
(3) Varshavsky, A. (1997) The ubiquitin system. Trends Biochem. Sci.
22, 383−387.
(4) Wilkinson, K. D. (2000) Ubiquitination and deubiquitination:
Targeting of proteins for degradation by the proteasome. Semin. Cell
Dev. Biol. 11, 141−148.
(5) Goldberg, A. L. (2003) Protein degradation and protection
against misfolded or damaged proteins. Nature 426, 895−899.
(6) Pickart, C. M., and Cohen, R. E. (2004) Proteasomes and their
kin: Proteases in the machine age. Nat. Rev. Mol. Cell Biol. 5, 177−187.
(7) Finley, D. (2009) Recognition and processing of ubiquitin-
protein conjugates by the proteasome. Annu. Rev. Biochem. 78, 477−
513.
(8) Baumeister, W., Walz, J., Zuhl, F., and Seemuller, E. (1998) The
proteasome: Paradigm of a self-compartmentalizing protease. Cell 92,
367−380.
(9) Matyskiela, M. E., and Martin, A. (2012) Design principles of a
universal protein degradation machine. J. Mol. Biol. 425, 199−213.
(10) Lander, G. C., Estrin, E., Matyskiela, M. E., Bashore, C.,
Nogales, E., and Martin, A. (2012) Complete subunit architecture of
the proteasome regulatory particle. Nature 482, 186−191.
(11) Lasker, K., Forster, F., Bohn, S., Walzthoeni, T., Villa, E.,
Unverdorben, P., Beck, F., Aebersold, R., Sali, A., and Baumeister, W.
(2012) Molecular architecture of the 26S proteasome holocomplex
determined by an integrative approach. Proc. Natl. Acad. Sci. U.S.A.
109, 1380−1387.
(12) Goldberg, A. L. (2007) Functions of the proteasome: From
protein degradation and immune surveillance to cancer therapy.
Biochem. Soc. Trans. 35, 12−17.
(13) Demartino, G. N., and Gillette, T. G. (2007) Proteasomes:
Machines for all reasons. Cell 129, 659−662.
(14) Guterman, A., and Glickman, M. H. (2004) Deubiquitinating
enzymes are IN/(trinsic to proteasome function). Curr. Protein Pept.
Sci. 5, 201−211.
(15) Yao, T., and Cohen, R. E. (2002) A cryptic protease couples
deubiquitination and degradation by the proteasome. Nature 419,
403−407.
(16) Verma, R., Aravind, L., Oania, R., McDonald, W. H., Yates, J. R.,
III, Koonin, E. V., and Deshaies, R. J. (2002) Role of Rpn11
metalloprotease in deubiquitination and degradation by the 26S
proteasome. Science 298, 611−615.
(17) Lee, M. J., Lee, B. H., Hanna, J., King, R. W., and Finley, D.
(2011) Trimming of ubiquitin chains by proteasome-associated
deubiquitinating enzymes. Mol Cell Proteomics. 10, R110.003871.
(18) Pickart, C. M. (2001) Mechanisms underlying ubiquitination.
Annu. Rev. Biochem. 70, 503−533.
(19) Schulman, B. A. (2011) Twists and turns in ubiquitin-like
protein conjugation cascades. Protein Sci. 20, 1941−1954.
(20) Pickart, C. M. (2000) Ubiquitin in chains. Trends Biochem. Sci.
25, 544−548.
(21) Haglund, K., and Dikic, I. (2005) Ubiquitylation and cell
signaling. EMBO J. 24, 3353−3359.
(22) Ikeda, F., and Dikic, I. (2008) Atypical ubiquitin chains: New
molecular signals. ‘Protein Modifications: Beyond the Usual Suspects’
review series. EMBO Rep. 9, 536−542.
(23) Fushman, D., and Wilkinson, K. D. (2011) Structure and
recognition of polyubiquitin chains of different lengths and linkage.
F1000 Biol. Rep. 3, 26.
(24) Komander, D., and Rape, M. (2012) The ubiquitin code. Annu.
Rev. Biochem. 81, 203−229.
(25) Kulathu, Y., and Komander, D. (2012) Atypical ubiquitylation:
The unexplored world of polyubiquitin beyond Lys48 and Lys63
linkages. Nat. Rev. Mol. Cell Biol. 13, 508−523.
(26) Chen, Z. J., and Sun, L. J. (2009) Nonproteolytic functions of
ubiquitin in cell signaling. Mol. Cell 33, 275−286.
(27) Komander, D., Clague, M. J., and Urbe, S. (2009) Breaking the
chains: Structure and function of the deubiquitinases. Nat. Rev. Mol.
Cell Biol. 10, 550−563.
(28) Komander, D. (2010) Mechanism, specificity and structure of
the deubiquitinases. Subcell. Biochem. 54, 69−87.
(29) Amerik, A. Y., and Hochstrasser, M. (2004) Mechanism and
function of deubiquitinating enzymes. Biochim. Biophys. Acta 1695,
189−207.
(30) Wilkinson, K. D. (1997) Regulation of ubiquitin-dependent
processes by deubiquitinating enzymes. FASEB J. 11, 1245−1256.
(31) Wilkinson, K. D. (2009) DUBs at a glance. J. Cell Sci. 122,
2325−2329.
Biochemistry Article
dx.doi.org/10.1021/bi4003106 | Biochemistry 2013, 52, 3564−35783576
130
(32) Nijman, S. M., Luna-Vargas, M. P., Velds, A., Brummelkamp, T.
R., Dirac, A. M., Sixma, T. K., and Bernards, R. (2005) A genomic and
functional inventory of deubiquitinating enzymes. Cell 123, 773−786.
(33) Love, K. R., Catic, A., Schlieker, C., and Ploegh, H. L. (2007)
Mechanisms, biology and inhibitors of deubiquitinating enzymes. Nat.
Chem. Biol. 3, 697−705.
(34) Reyes-Turcu, F. E., Ventii, K. H., and Wilkinson, K. D. (2009)
Regulation and cellular roles of ubiquitin-specific deubiquitinating
enzymes. Annu. Rev. Biochem. 78, 363−397.
(35) Tsou, W. L., Sheedlo, M. J., Morrow, M. E., Blount, J. R.,
McGregor, K. M., Das, C., and Todi, S. V. (2012) Systematic analysis
of the physiological importance of deubiquitinating enzymes. PLoS
One 7, e43112.
(36) Borodovsky, A., Kessler, B. M., Casagrande, R., Overkleeft, H. S.,
Wilkinson, K. D., and Ploegh, H. L. (2001) A novel active site-directed
probe specific for deubiquitylating enzymes reveals proteasome
association of USP14. EMBO J. 20, 5187−5196.
(37) Yao, T., Song, L., Xu, W., DeMartino, G. N., Florens, L.,
Swanson, S. K., Washburn, M. P., Conaway, R. C., Conaway, J. W., and
Cohen, R. E. (2006) Proteasome recruitment and activation of the
Uch37 deubiquitinating enzyme by Adrm1. Nat. Cell Biol. 8, 994−
1002.
(38) Lam, Y. A., Xu, W., DeMartino, G. N., and Cohen, R. E. (1997)
Editing of ubiquitin conjugates by an isopeptidase in the 26S
proteasome. Nature 385, 737−740.
(39) Hanna, J., Hathaway, N. A., Tone, Y., Crosas, B., Elsasser, S.,
Kirkpatrick, D. S., Leggett, D. S., Gygi, S. P., King, R. W., and Finley,
D. (2006) Deubiquitinating enzyme Ubp6 functions noncatalytically
to delay proteasomal degradation. Cell 127, 99−111.
(40) Hu, M., Li, P., Song, L., Jeffrey, P. D., Chenova, T. A.,
Wilkinson, K. D., Cohen, R. E., and Shi, Y. (2005) Structure and
mechanisms of the proteasome-associated deubiquitinating enzyme
USP14. EMBO J. 24, 3747−3756.
(41) Koulich, E., Li, X., and DeMartino, G. N. (2008) Relative
structural and functional roles of multiple deubiquitylating proteins
associated with mammalian 26S proteasome. Mol. Biol. Cell 19, 1072−
1082.
(42) Lee, B. H., Lee, M. J., Park, S., Oh, D. C., Elsasser, S., Chen, P.
C., Gartner, C., Dimova, N., Hanna, J., Gygi, S. P., Wilson, S. M., King,
R. W., and Finley, D. (2010) Enhancement of proteasome activity by a
small-molecule inhibitor of USP14. Nature 467, 179−184.
(43) D’Arcy, P., Brnjic, S., Olofsson, M. H., Fryknas, M., Lindsten, K.,
De Cesare, M., Perego, P., Sadeghi, B., Hassan, M., Larsson, R., and
Linder, S. (2011) Inhibition of proteasome deubiquitinating activity as
a new cancer therapy. Nat. Med. 17, 1636−1640.
(44) D’Arcy, P., and Linder, S. (2012) Proteasome deubiquitinases as
novel targets for cancer therapy. Int. J. Biochem. Cell Biol. 44, 1729−
1738.
(45) Lam, Y. A., DeMartino, G. N., Pickart, C. M., and Cohen, R. E.
(1997) Specificity of the ubiquitin isopeptidase in the PA700
regulatory complex of 26 S proteasomes. J. Biol. Chem. 272, 28438−
28446.
(46) Stone, M., Hartmann-Petersen, R., Seeger, M., Bech-Otschir, D.,
Wallace, M., and Gordon, C. (2004) Uch2/Uch37 is the major
deubiquitinating enzyme associated with the 26S proteasome in fission
yeast. J. Mol. Biol. 344, 697−706.
(47) Larsen, C. N., Krantz, B. A., and Wilkinson, K. D. (1998)
Substrate specificity of deubiquitinating enzymes: Ubiquitin C-
terminal hydrolases. Biochemistry 37, 3358−3368.
(48) Misaghi, S., Galardy, P. J., Meester, W. J., Ovaa, H., Ploegh, H.
L., and Gaudet, R. (2005) Structure of the ubiquitin hydrolase UCH-
L3 complexed with a suicide substrate. J. Biol. Chem. 280, 1512−1520.
(49) Das, C., Hoang, Q. Q., Kreinbring, C. A., Luchansky, S. J.,
Meray, R. K., Ray, S. S., Lansbury, P. T., Ringe, D., and Petsko, G. A.
(2006) Structural basis for conformational plasticity of the Parkinson’s
disease-associated ubiquitin hydrolase UCH-L1. Proc. Natl. Acad. Sci.
U.S.A. 103, 4675−4680.
(50) Johnston, S. C., Larsen, C. N., Cook, W. J., Wilkinson, K. D.,
and Hill, C. P. (1997) Crystal structure of a deubiquitinating enzyme
(human UCH-L3) at 1.8 Å resolution. EMBO J. 16, 3787−3796.
(51) Hamazaki, J., Iemura, S., Natsume, T., Yashiroda, H., Tanaka, K.,
and Murata, S. (2006) A novel proteasome interacting protein recruits
the deubiquitinating enzyme UCH37 to 26S proteasomes. EMBO J.
25, 4524−4536.
(52) Husnjak, K., Elsasser, S., Zhang, N., Chen, X., Randles, L., Shi,
Y., Hofmann, K., Walters, K. J., Finley, D., and Dikic, I. (2008)
Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature 453,
481−488.
(53) Schreiner, P., Chen, X., Husnjak, K., Randles, L., Zhang, N.,
Elsasser, S., Finley, D., Dikic, I., Walters, K. J., and Groll, M. (2008)
Ubiquitin docking at the proteasome through a novel pleckstrin-
homology domain interaction. Nature 453, 548−552.
(54) Qiu, X. B., Ouyang, S. Y., Li, C. J., Miao, S., Wang, L., and
Goldberg, A. L. (2006) hRpn13/ADRM1/GP110 is a novel
proteasome subunit that binds the deubiquitinating enzyme,
UCH37. EMBO J. 25, 5742−5753.
(55) Yao, T., Song, L., Jin, J., Cai, Y., Takahashi, H., Swanson, S. K.,
Washburn, M. P., Florens, L., Conaway, R. C., Cohen, R. E., and
Conaway, J. W. (2008) Distinct modes of regulation of the Uch37
deubiquitinating enzyme in the proteasome and in the Ino80
chromatin-remodeling complex. Mol. Cell 31, 909−917.
(56) Nishio, K., Kim, S. W., Kawai, K., Mizushima, T., Yamane, T.,
Hamazaki, J., Murata, S., Tanaka, K., and Morimoto, Y. (2009) Crystal
structure of the de-ubiquitinating enzyme UCH37 (human UCH-L5)
catalytic domain. Biochem. Biophys. Res. Commun. 390, 855−860.
(57) Burgie, S. E., Bingman, C. A., Soni, A. B., and Phillips, G. N.
(2012) Structural characterization of human Uch37. Proteins 80, 649−
654.
(58) Maiti, T. K., Permaul, M., Boudreaux, D. A., Mahanic, C.,
Mauney, S., and Das, C. (2011) Crystal structure of the catalytic
domain of UCHL5, a proteasome-associated human deubiquitinating
enzyme, reveals an unproductive form of the enzyme. FEBS J. 278,
4917−4926.
(59) White, R. R., Miyata, S., Papa, E., Spooner, E., Gounaris, K.,
Selkirk, M. E., and Artavanis-Tsakonas, K. (2011) Characterisation of
the Trichinella spiralis deubiquitinating enzyme, TsUCH37, an
evolutionarily conserved proteasome interaction partner. PLoS
Neglected Trop. Dis. 5, e1340.
(60) Borodovsky, A., Ovaa, H., Kolli, N., Gan-Erdene, T., Wilkinson,
K. D., Ploegh, H. L., and Kessler, B. M. (2002) Chemistry-based
functional proteomics reveals novel members of the deubiquitinating
enzyme family. Chem. Biol. 9, 1149−1159.
(61) Holyoak, T., Fenn, T. D., Wilson, M. A., Moulin, A. G., Ringe,
D., and Petsko, G. A. (2003) Malonate: A versatile cryoprotectant and
stabilizing solution for salt-grown macromolecular crystals. Acta
Crystallogr. D59, 2356−2358.
(62) Otwinowski, Z., and Minor, W. (1997) Processing of X-ray
Diffraction Data Collected in Oscillation Mode. Methods Enzymol. 276,
307−326.
(63) Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I.
W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., and Grosse-
Kunstleve, R. W. (2010) PHENIX: A comprehensive Python-based
system for macromolecular structure solution. Acta Crystallogr. D66,
213−221.
(64) Emsley, P., and Cowtan, K. (2004) Coot: Model-building tools
for molecular graphics. Acta Crystallogr. D60, 2126−2132.
(65) Schuck, P. (2000) Size-distribution analysis of macromolecules
by sedimentation velocity ultracentrifugation and lamm equation
modeling. Biophys. J. 78, 1606−1619.
(66) Arnold, K., Bordoli, L., Kopp, J., and Schwede, T. (2006) The
SWISS-MODEL workspace: A web-based environment for protein
structure homology modelling. Bioinformatics 22, 195−201.
(67) Case, D., Darden, T., Cheatham, T., III, Simmerling, C., Wang,
J., Duke, R., Luo, R., Walker, R., Zhang, W., and Merz, K. (2012)
AMBER 12, University of California, San Francisco.
Biochemistry Article
dx.doi.org/10.1021/bi4003106 | Biochemistry 2013, 52, 3564−35783577
131
(68) Darden, T., York, D., and Pedersen, L. (1993) Particle mesh
Ewald: An N·log (N) method for Ewald sums in large systems. J.
Chem. Phys. 98, 10089.
(69) Ryckaert, J.-P., Ciccotti, G., and Berendsen, H. J. (1977)
Numerical integration of the cartesian equations of motion of a system
with constraints: Molecular dynamics of n-alkanes. J. Comput. Phys. 23,
327−341.
(70) Misaghi, S., Ottosen, S., Izrael-Tomasevic, A., Arnott, D.,
Lamkanfi, M., Lee, J., Liu, J., O’Rourke, K., Dixit, V. M., and Wilson, A.
C. (2009) Association of C-terminal ubiquitin hydrolase BRCA1-
associated protein 1 with cell cycle regulator host cell factor 1. Mol.
Cell. Biol. 29, 2181−2192.
(71) Sanchez-Pulido, L., Kong, L., and Ponting, C. P. (2012) A
common ancestry for BAP1 and Uch37 regulators. Bioinformatics 28,
1953−1956.
(72) Chen, V., Arendall, W., Headd, J., Keedy, D., Immormino, R.,
Kapral, G., Murray, L., Richardson, J., and Richardson, D. (2010)
MolProbity: All-atom structure validation for macromolecular
crystallography. Acta Crystallogr. D66, 12−21.
(73) Johnston, S. C., Riddle, S. M., Cohen, R. E., and Hill, C. P.
(1999) Structural basis for the specificity of ubiquitin C-terminal
hydrolases. EMBO J. 18, 3877−3887.
(74) Zhou, Z. R., Zhang, Y. H., Liu, S., Song, A. X., and Hu, H. Y.
(2012) Length of the active-site crossover loop defines the substrate
specificity of ubiquitin C-terminal hydrolases for ubiquitin chains.
Biochem. J. 441, 143−149.
(75) Boudreaux, D. A., Chaney, J., Maiti, T. K., and Das, C. (2012)
Contribution of active site glutamine to rate enhancement in ubiquitin
C-terminal hydrolases. FEBS J. 279, 1106−1118.
(76) Boudreaux, D. A., Maiti, T. K., Davies, C. W., and Das, C.
(2010) Ubiquitin vinyl methyl ester binding orients the misaligned
active site of the ubiquitin hydrolase UCHL1 into productive
conformation. Proc. Natl. Acad. Sci. U.S.A. 107, 9117−9122.
(77) Popp, M. W., Artavanis-Tsakonas, K., and Ploegh, H. L. (2009)
Substrate filtering by the active site crossover loop in UCHL3 revealed
by sortagging and gain-of-function mutations. J. Biol. Chem. 284,
3593−3602.
(78) Artavanis-Tsakonas, K., Weihofen, W. A., Antos, J. M., Coleman,
B. I., Comeaux, C. A., Duraisingh, M. T., Gaudet, R., and Ploegh, H. L.
(2010) Characterization and structural studies of the Plasmodium
falciparum ubiquitin and Nedd8 hydrolase UCHL3. J. Biol. Chem. 285,
6857−6866.
(79) Hu, M., Li, P., Li, M., Li, W., Yao, T., Wu, J. W., Gu, W., Cohen,
R. E., and Shi, Y. (2002) Crystal structure of a UBP-family
deubiquitinating enzyme in isolation and in complex with ubiquitin
aldehyde. Cell 111, 1041−1054.
(80) Eddins, M. J., Varadan, R., Fushman, D., Pickart, C. M., and
Wolberger, C. (2007) Crystal structure and solution NMR studies of
Lys48-linked tetraubiquitin at neutral pH. J. Mol. Biol. 367, 204−211.
(81) Reyes-Turcu, F. E., Shanks, J. R., Komander, D., and Wilkinson,
K. D. (2008) Recognition of polyubiquitin isoforms by the multiple
ubiquitin binding modules of isopeptidase T. J. Biol. Chem. 283,
19581−19592.
(82) Sato, Y., Yoshikawa, A., Yamagata, A., Mimura, H., Yamashita,
M., Ookata, K., Nureki, O., Iwai, K., Komada, M., and Fukai, S. (2008)
Structural basis for specific cleavage of Lys 63-linked polyubiquitin
chains. Nature 455, 358−362.
(83) Datta, A. B., Hura, G. L., and Wolberger, C. (2009) The
structure and conformation of Lys63-linked tetraubiquitin. J. Mol. Biol.
392, 1117−1124.
(84) Komander, D., Reyes-Turcu, F., Licchesi, J. D., Odenwaelder, P.,
Wilkinson, K. D., and Barford, D. (2009) Molecular discrimination of
structurally equivalent Lys 63-linked and linear polyubiquitin chains.
EMBO Rep. 10, 466−473.
(85) Tenno, T., Fujiwara, K., Tochio, H., Iwai, K., Morita, E. H.,
Hayashi, H., Murata, S., Hiroaki, H., Sato, M., Tanaka, K., and
Shirakawa, M. (2004) Structural basis for distinct roles of Lys63- and
Lys48-linked polyubiquitin chains. Genes Cells 9, 865−875.
(86) Ventii, K. H., Devi, N. S., Friedrich, K. L., Chernova, T. A.,
Tighiouart, M., Van Meir, E. G., and Wilkinson, K. D. (2008) BRCA1-
associated protein-1 is a tumor suppressor that requires deubiquitinat-
ing activity and nuclear localization. Cancer Res. 68, 6953−6962.
(87) Scheuermann, J. C., de Ayala Alonso, A. G., Oktaba, K., Ly-
Hartig, N., McGinty, R. K., Fraterman, S., Wilm, M., Muir, T. W., and
Muller, J. (2010) Histone H2A deubiquitinase activity of the
Polycomb repressive complex PR-DUB. Nature 465, 243−247.
Biochemistry Article
dx.doi.org/10.1021/bi4003106 | Biochemistry 2013, 52, 3564−35783578
132
research papers





Received 12 October 2012
Accepted 22 March 2013
# 2013 International Union of Crystallography
Printed in Singapore – all rights reserved
Integrated nonlinear optical imaging microscope
for on-axis crystal detection and centering at a
synchrotron beamline
Jeremy T. Madden,a Scott J. Toth,a Christopher M. Dettmar,a Justin A. Newman,a
Robert A. Oglesbee,a Hartmut G. Hedderich,a R. Michael Everly,a Michael Becker,b
Judith A. Ronau,a Susan K. Buchanan,c Vadim Cherezov,d Marie E. Morrow,a
Shenglan Xu,b Dale Ferguson,b Oleg Makarov,b Chittaranjan Das,a
Robert Fischettib and Garth J. Simpsona*
aDepartment of Chemistry, Purdue University, 560 Oval Drive, West Lafayette, IN 47906, USA,
bGM/CA@APS, Advanced Photon Source, Argonne National Laboratory, 9700 South Cass Avenue,
Argonne, IL 60439, USA, cNIDDK, National Institutes of Health, Building 50, Room 4503, 50 South
Drive, Bethesda, MD 20814, USA, and dDepartment of Molecular Biology, The Scripps Research
Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA. E-mail: gsimpson@purdue.edu
Nonlinear optical (NLO) instrumentation has been integrated with synchrotron
X-ray diffraction (XRD) for combined single-platform analysis, initially
targeting applications for automated crystal centering. Second-harmonic-
generation microscopy and two-photon-excited ultraviolet fluorescence micro-
scopy were evaluated for crystal detection and assessed by X-ray raster
scanning. Two optical designs were constructed and characterized; one
positioned downstream of the sample and one integrated into the upstream
optical path of the diffractometer. Both instruments enabled protein crystal
identification with integration times between 80 and 150 ms per pixel,
representing a 103–104-fold reduction in the per-pixel exposure time relative
to X-ray raster scanning. Quantitative centering and analysis of phenylalanine
hydroxylase from Chromobacterium violaceum cPAH, Trichinella spiralis
deubiquitinating enzyme TsUCH37, human -opioid receptor complex kOR-
T4L produced in lipidic cubic phase (LCP), intimin prepared in LCP, and -
cellulose samples were performed by collecting multiple NLO images. The
crystalline samples were characterized by single-crystal diffraction patterns,
while -cellulose was characterized by fiber diffraction. Good agreement was
observed between the sample positions identified by NLO and XRD raster
measurements for all samples studied.
Keywords: XRD; NLO; SHG; SONICC; centering; protein; TPE-UVF; microscopy;
LCP; two-photon.
1. Introduction
The high photon flux and energy tunability of synchrotron
radiation sources have made them indispensable tools for
X-ray analysis, with applications spanning protein structure
determination through materials science and nanotechnology
(Rasmussen et al., 2011; Moukhametzianov et al., 2008; Bates
et al., 2006; Berger et al., 2010; Dauter, 2006; Ihee et al., 2010;
le Maire et al., 2011; Parker et al., 2006; Riekel et al., 2005).
The increasing drive toward tighter focusing has enabled
structure determination on ever-smaller crystals and sub-
domains within materials, but presents growing challenges for
reliable crystal centering. These challenges are particularly
relevant for protein crystal diffraction, in which the drive
toward fully automated X-ray diffraction analysis at
synchrotron sources has introduced bottlenecks in sample
positioning (Andrey et al., 2004; Moukhametzianov et al., 2008;
Pothineni et al., 2006; Aishima et al., 2010; Cherezov et al.,
2009; Stepanov et al., 2011a). Diffraction-quality protein
crystals are typically obtained through crystallization screen-
ings, followed by optimization, and then are placed into cryo-
loops, which are flash-cooled in liquid nitrogen to reduce
X-ray damage and aid in sample handling (Dobrianov et al.,
1999; Karain et al., 2002). High-throughput methods for
automated crystal positioning are frustrated by complications
of reliable centering of smaller and smaller protein crystals
within more complex and turbid matrices. The current most
reliable methods for crystal centering involve rastering the
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sample using a focused X-ray beam (Accardo et al., 2010;
Hilgart et al., 2011; Cherezov et al., 2009; Stepanov et al., 2011a;
Aishima et al., 2010; Song et al., 2007). From the resulting
X-ray diffraction images recorded as a function of sample
position in the beam, protein crystals are centered based on
the locations of strongest Bragg-like diffraction. X-ray fluor-
escence raster is also relatively fast, but it requires a conve-
nient X-ray fluorescent element to be present in the crystal
(Stepanov et al., 2011a).
While generally successful, X-ray raster scanning suffers
from several limitations. First, the method is relatively slow,
often utilizing >2 s per pixel (raster cell), corresponding to
analysis times from several minutes up to an hour depending
on the number of cells in the raster grid and on the exposure
time (Aishima et al., 2010). Rastering is commonly performed
first with a coarse grid, and then a finer grid, to minimize the
number of cells, and to increase speed. The total pixel number
is in turn dependent on the size of the X-ray beam, the speed
of the detector and analysis, as well as the scanned size of the
cryo-loop and the crystal itself (Cherezov et al., 2009; Song
et al., 2007). Recent advances in diffraction image read times
using single-photon-counting arrays (pixel array detectors)
(Broennimann et al., 2006), allowing integration times as low
as 2 ms per image (Aishima et al., 2010), can significantly
reduce the time frame for raster scanning measurements.
However, the time required for raster scanning will still ulti-
mately be limited by the collective times required to obtain
sufficient signal to noise (S/N) in a given pixel, to translate the
sample through the X-ray source, and to reconstruct the
crystal positions based on automated analysis of the compiled
diffraction images. Diffraction is a relatively inefficient process
with far more X-ray photons absorbed or inelastically scat-
tered than detected for diffraction analysis, contributing to
sample damage, even under the cryogenic conditions typically
utilized. With small crystals or beams, incident X-ray inten-
sities must be increased accordingly to achieve diffracted
intensities equivalent to those for large crystals, thereby
increasing absorbed X-ray dose and exacerbating damage.
Alternative methods for automated loop centering based on
optical imaging include bright-field image analysis and ultra-
violet fluorescence (UVF) microscopy, which takes advantage
of intrinsic fluorescent properties of protein crystals (Jain &
Stojanoff, 2007; Vernede et al., 2006; Pohl et al., 2004; Andrey
et al., 2004; Pothineni et al., 2006). However, algorithms for
protein crystal centering (e.g. based on crystal edge-finding
algorithms) are error-prone for microcrystals and turbid
matrices, such as lipidic cubic phase (LCP). Methods opti-
mized for analysis within the mother liquor often prove
unreliable for a loop-mounted crystal, in part because algo-
rithms often cannot easily distinguish between the loop,
features in the cryo-cooled mother-liquor and the crystal.
Furthermore, both bright-field and UVF imaging are chal-
lenging to reliably implement in turbid matrices, where optical
scattering frustrates reliable crystal imaging. UVF also has
a potential disadvantage of inducing UV photodamage to
samples from long exposures, or in highly labile proteins, but
the exposure times required for imaging are typically short
enough to minimize such effects (Vernede et al., 2006; Chen et
al., 2009; Nanao & Ravelli, 2006).
More recently, nonlinear optical imaging (NLO) methods
such as second-harmonic generation (SHG) and two-photon-
excited UV fluorescence (TPE-UVF) have emerged as viable
alternatives for high-contrast crystal visualization (Kissick et
al., 2010; Madden et al., 2011). SHG, or the frequency doubling
of light, is symmetry forbidden in disordered media (e.g.
amorphous protein aggregates or proteins in solution) but is
allowed for certain classes of crystals (Haupert & Simpson,
2011). Fortuitously, the chirality intrinsic to proteins typically
results in the adoption of SHG-active crystal classes. Recent
quantum chemical calculations suggest an SHG coverage of
approximately 84% of protein crystals in the Protein Crystal
Database using an optimized instrument (Haupert et al.,
2012). TPE-UVF provides a complimentary method to SHG
for protein crystal detection, with contrast dependent on the
presence of aromatic side-chains (primarily tryptophan),
independent of crystallinity. Crystals that are weakly active to
SHG imaging but contain fluorescent amino acid residues can
be detected (Madden et al., 2011). Furthermore, TPE-UVF
can aid in distinguishing SHG-active small-molecule and salt
crystals from protein crystals.
The high selectivity for crystals and negligible background
from disordered protein aggregates typically produces high-
contrast SHG images, which are highly compatible with
automated image analysis algorithms designed for protein
crystal detection and centering (Haupert & Simpson, 2011).
SHG measurements have recently enabled crystal detection
for diffraction centering using off-line instrumentation
(Kissick et al., 2013), in which protein crystals were first
imaged under cryogenic conditions with an SHG microscope,
and then manually compared with diffraction images obtained
by X-ray raster scanning with good agreement. A major
benefit of NLO instruments is the reduction in time required
to determine crystal locations with high contrast, as
measurements for an entire loop can be obtained in as little as
a few seconds, compared with tens of minutes routinely
required for X-ray raster imaging. The spatial resolution of
NLO instruments is also high (1–2 mm), whereas X-ray
diffraction (XRD) rastering with this type of resolution would
take substantially longer to scan an area equivalent to that of
the entire NLO image (>72 h at 1 s per pixel for a 512  512
pixel image). Furthermore, reducing the reliance on X-ray
raster imaging would minimize X-ray-induced sample damage
(Hilgart et al., 2011; Ravelli & Garman, 2006).
By integrating SHG and TPE-UVF imaging directly into a
synchrotron X-ray diffraction beamline, the robotic controls,
automated positioning capabilities, cryogenics and other
beamline utilities of high-throughput synchrotron facilities can
be leveraged. However, the spatial constraints of a typical
synchrotron X-ray experimental hutch represent a nontrivial
hurdle for development of compatible NLO instrumentation.
Typical research NLO instruments occupy a large footprint
(an optical table approximately 120 cm  300 cm), far greater
than the space available on a typical beamline. In this
work, two complementary prototypes for an on-line compa-
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tible instrument combining synchrotron
XRD and NLO imaging are described.
Assessment of these systems was
performed by direct comparisons
between NLO images and those
obtained by X-ray diffraction rastering.
2. Experimental methods
Two separate instruments were
designed and constructed for inte-
grating XRD and NLO imaging, each
with its own advantages and limitations.
The upstream version introduced the
incident light coaxial and parallel with
the direction of the X-ray beam path,
while the downstream system was
coaxial and anti-parallel. The upstream
version was designed to fully integrate
with the existing optical path, while the
downstream version was optimized for
high flexibility and compatibility with
diverse beamline configurations. Both
systems were rated as Class I laser
systems on-site, with enclosed beam
paths, shutters and interlocks to ensure
no exposed collimated optical radiation.
The integrated NLO microscopes were
installed at beamlines 23-ID-B and 23-
ID-D at the Advanced Photon Source
(APS) at Argonne National Laboratory
in Argonne, IL, USA. A basic schematic
of the instruments and beam paths as they were installed on
the synchrotron beamline can be seen in Fig. 1. Detailed
descriptions and photographs are provided.
2.1. Integrated nonlinear optical microscope designs
The upstream illumination NLO system was designed to sit
above the existing instrumentation at GM/CA beamline 23-
ID-B at the APS, and couple directly into the existing optical
path. A Fianium FemtoPower 1060 ultrafast fiber laser was
utilized, producing 160 fs pulses centered around 1060 nm,
with a 50 MHz repetition rate, maximum power of 1.5 W,
allowing for a maximum power of 140 mW at the sample,
with 80% of the overall loss arising from the objective. The
Fianium source was composed of an oscillator coupled via a
1.5 m fiber to a dispersion compensator and free-space coupler
unit, with dimensions of approximately 15 cm 13 cm 8 cm.
A heated doubling crystal (Newlight Photonics Inc.,
SHG1663-IM, HTS 85141000) was permanently assembled in
the beam path, with the fundamental beam focused into the
crystal with a plano-convex lens ( f = 35 mm) and collimated
with another plano-convex lens ( f = 100 mm) after the
doubling crystal. The efficiency of SHG from the doubling
crystal was controlled by either introducing or removing a
1064 nm zero-order half-wave plate using a flip mount (New
Focus, 8892-K). The scanning assembly consisted of a
galvanometer mirror (Cambridge Technology, 6210H) and
resonant scanning mirror (Cambridge Technology, 1-003-
3002509), controlling the beam position on the horizontal
slow-scan and vertical fast-scan axes, respectively. The beam
was directed into a telocentric lens pair consisting of two
plano-convex lenses ( f = 75 mm and f = 250 mm) leading to an
additional 3.3 beam expansion after the scan head. The
incident light then reflected off a dichroic mirror stack
(Semrock, PBP01-529/23-25x36 and Chroma, 900dcsp)
designed to reflect 1060 nm and s-polarized 530 nm incident
light. The p-polarized component of the returning 530 nm light
was transmitted by this same dichroic for epi-detected SHG
(i.e. SHG detected in the backward direction through the same
objective as the incident light). High-reflectivity dichroic
mirrors for both 1060 nm and 530 nm light (Semrock, FF550-
Di01-25x36) delivered both wavelengths to the back aperture
of the 10 objective (Optem, 28-21-10), which was modified
with a 1.2 mm hole bored through the center to allow
X-ray access. In epi, the p-polarized SHG returning through
the dichroic mirror was passed through a bandpass filter
set (Chroma, HQ530/30m and CVI, 03FCG567/KG3) and into
a compact photomultiplier tube (PMT) module (Hamamatsu,
H10722-10). SHG and TPE-UVF were collected in the
transmission direction by a plano-convex lens ( f = 25.4 mm)
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Figure 1
(a) Schematic of the downstream NLO microscope; (b) schematic of the upstream NLO
microscope; (c) close-up view of the downstream NLO microscope, with the solid arrow
representing incident laser propagation (red, 1060 nm) and dashed arrows representing the
frequency-doubled signal (green, SHG at 530 nm); (d) close-up view of the upstream NLO
microscope, with solid arrows representing incident laser propagation (red, 1060 nm; green, 530 nm)
and dashed arrows representing the measured signal (green, SHG at 530 nm; blue, TPE-UVF).
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affixed to a right-angle prism using optical epoxy (Norland
Optical Adhesive 63). Another plano-convex lens ( f =
25.4 mm) coupled the detected light into a near-UV-compa-
tible liquid light guide (Oriel Instruments, 77554) collimated
with a plano-convex lens ( f = 25.4 mm) into the detection
assembly. Both the SHG and TPE-UVF were then reflected
off a primary dichroic beam splitter (Semrock, FF555-Di03-
25x36), then separated at a second dichroic beam splitter
(Chroma, z1064rdc-sp) for selective detection of SHG
(through Chroma, HQ530/30m and CVI, 03FCG567/KG3
filters) and TPE-UVF (through Semrock, SP01-532RS-25 and
FF01-440/SP-25 filters). Both the SHG and TPE-UVF were
focused onto the faces of the PMT modules (Hamamatsu,
H10722-10) by a plano-convex lens ( f = 60 mm) positioned
between the primary and secondary dichroic beam splitters.
Backlight illumination was achieved using an LED (ThorLabs,
MCWHL2) passing through the primary dichroic beam
splitter and into the liquid light guide. The illumination light
was then focused through the trans-SHG/TPE-UVF collection
optics and onto the sample.
The downstream NLO system was also designed with the
optical axis of the objective co-axial with the axis of X-ray
propagation [Figs. 1(a) and 1(b)], using a similar laser source.
The size constraints associated with this beamline, specifically
the restrictions imposed by the support structure of the
beamline and the area and instruments surrounding the
sample, limited the available footprint of the NLO system to
39 cm  19 cm. The scanning assembly was composed of dual
galvanometers (Cambridge Technologies, 6210HSM40B),
mounted in a two-dimensional galvo 30 mm cage cube
(Thorlabs, GCM002), with each scanning mirror rotating
along either the x or y axis. With the scan head inducing a 90
turn into the beam path, the incident light was directed
through a telocentric lens pair, mounted in a 30 mm cage cube,
and composed of an aspheric lens ( f = 10 mm) and a plano-
convex lens ( f = 50 mm), leading to a 5 beam expansion. The
incident light was then focused onto the sample by a long-
working-distance IR 10 objective (Mitutoyo, NT46-403)
generating SHG at 530 nm. Up to 650 mW of 1064 nm light
could be delivered to the sample with this system with the use
of the IR objective (compared with 140 mWwith the upstream
system). The SHG was detected in the epi-direction, collected
through the incident objective and reflected through a filter set
and onto a compact PMT module (Hamamatsu, H10722-10)
by a dichroic mirror (Omega Optical, 580DCLP) centered
around 532 nm and mounted in a rotatable kinematically
controlled cage cube platform. The SHG signal was detected
through a filter set composed of a KG3 (Thorlabs, FGS900)
and 530 nm filter (Chroma, z532/10x). Bright-field images
were also collected in the epi-direction using a module
composed of an aspheric lens ( f = 20 mm) and a CMOS
camera (Thorlabs, DCC1645C), manually inserted when
bright-field images were desired. Including the laser source,
the total footprint of the microscope was 25 cm  15 cm 
15 cm. The microscope was translated to the sample, at a
height of 1.4 m, to perform SHG detection and centering
measurements. The foundation of the microscope was a
high-precision long-travel translation stage (Newport,
M-IMS300V), and its electronics box (Newport, ESP 300,
three-axis motion controller), capable of translating the laser
pulse-compressor/output coupler, the microscope and the
support structure to and from the sample between X-ray
measurements, corresponding to approximately 20 cm of
travel, with an absolute accuracy of 2 mm.
The electronics package was designed and constructed in
collaboration with the Jonathan Amy Facility for Chemical
Instrumentation at Purdue University (JAFCI). The electro-
nics package integrated the electronics associated with the
microscope, including the power supplies, control boards and
data acquisition card (National Instruments), into a compact
housing for easy mounting and transport, with a footprint of
46 cm 61 cm  31 cm. Data were acquired as photon counts
using a gated multi-scalar card (Becker & Hickl, PMS-400a),
controlled using a custom-designed Labview program, which
was also written in collaboration with JAFCI. Data recon-
struction and imaging were completed through ImageJ (NIH,
2011).
2.2. X-ray raster scan scheme
XRD analysis and NLO images were acquired on all
samples studied on 23-ID-B. Diffraction of kOR-T4L was
acquired with a 5 mm-diameter X-ray beam, 5 5 mm cell size,
12.0 keV X-ray beam, with 1 s exposure times, a photon flux
of 2.7  1010 photons s1 (full unattenuated beam) and a
detector distance of 300 mm. Diffraction of TsUCH37 was
acquired with a 10 mm-diameter X-ray beam, a 10  10 mm
cell, a photon flux of 1.3  1010 photons s1 (10-fold
attenuation) and detector distance of 300 mm. Diffraction of
-cellulose was acquired with a 10 mm-diameter X-ray beam,
a 10  10 mm X-ray beam with a photon flux of 2.7 
109 photons s1 (50-fold attenuation) and detector distance of
300 mm. The resulting NLO images and XRD raster
measurements were compared using ImageJ and JBluIce
(Hilgart et al., 2011), which employs DISTL (Zhang et al.,
2006), to assess the degree of correlation of the sample posi-
tion within the loop. The boundaries of the raster grids and
raster cell sizes were defined using the software GUI JBluIce
(Stepanov et al., 2011b). Bragg candidates, which estimate the
number of well-ordered reflections, were generated for each
X-ray diffraction image; they are shown color-coded in the
figures as unsmoothed XRD raster images. The X-ray beam
size was adjusted using a mini-beam collimator (Fischetti et al.,
2009).
3. Sample materials
Phenylalanine hydroxylase from Chromobacterium violaceum
(cPAH) was purified as a glutathione s-transferase (GST)
fusion protein. The GST tag was cleaved with PreScission
protease (GE Biosciences). For crystallization, cPAH was
concentrated to 10 mg ml1 in a solution of 5 mMHEPES, pH
7.4. Crystals of cPAH were obtained at ambient temperature
utilizing hanging-drop vapor diffusion from solution 43 of
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Hampton Research’s PEG/Ion 2 screen [0.1M Na-HEPES,
pH 7.0, 0.01M magnesium chloride hexahydrate, 0.005M
nickel (II) chloride hexahydrate and 15% w/v PEG 3350] with
8.3 mM hexammine cobalt (III) chloride and 8.3 mM guani-
dine hydrochloride as additives. Crystals were briefly soaked
in 25% ethylene glycol and then flash-cooled in liquid
nitrogen.
Crystals of human -opioid receptor in complex with an
antagonist JDTic were obtained as described by Wu et al.
(2012). Briefly, the human -opioid receptor sequence was
modified by fusing T4 lysozyme (T4L) into intracellular loop 3
(Gly261–Arg263), performing N/C-terminal truncations
(Glu2Ala42, Arg359Val380) and introducing a single
point mutation Ile1353.29Leu. The resulting construct kOR-
T4L was expressed in baculovirus infected sf9 insect cells.
Receptor was extracted from isolated membranes using
dodecylmaltoside/cholesterol hemisuccinate detergent
mixture, purified by metal-affinity chromatography, and
concentrated to 40 mg ml1. Lipidic cubic phase crystal-
lization was performed as previously described (Caffrey &
Cherezov, 2009; Cherezov et al., 2004), by mixing protein
solution with 10% cholesterol in monoolein at 2/3 protein
solution/lipid ratio, and dispensing 50 nL protein laden LCP
boluses overlaid with 800 nL precipitant solutions in a 96-well
glass sandwich plate (Marienfeld) (Cherezov & Caffrey, 2003)
using a NT8-LCP crystallization robot (Formulatrix). Crystals
were obtained in 100 mM sodium citrate pH 5.8–6.4, 28–32%
(v/v) PEG 400, 350–450 mM potassium nitrate, and were
harvested directly from LCP matrix using MiTeGen micro-
mounts and flash-cooled in liquid nitrogen.
The catalytic domain of Trichinella spiralis deubiquitinating
enzyme UCH37 was expressed in E. coli as a GST-fused
construct, purified on a glutathione-agarose column,
complexed with ubiquitin vinyl methyl ester (UBVME), and
subsequently purified by ion-exchange chromatography.
Crystals of this complex, hereafter referred to simply as
TsUCH37-UbVME complex, were grown by hanging-drop
vapor diffusion in 3M ammonium sulfate, 0.1M bicine pH 9.0,
and 2 mM l-glutathione (mixture of reduced and oxidized)
over two days at room temperature.
The -cellulose was prepared from pulpwood that under-
went both the Kraft process and subsequent mercerization
(Sixta et al., 2004; Takai & Colvin, 1978).
A construct encoding the membrane domain of E. coli
O157:H7 intimin was expressed, purified and crystallized as
described previously (Fairman et al., 2012). Briefly, Int208-449
was expressed in the outer membranes of E. coli BL21(DE3)
cells, extracted with the detergent Elugent (Calbiochem), and
purified by Ni-NTA affinity and anion-exchange chroma-
tography using buffers containing dodecyl maltoside
(Anatrace). Size-exclusion chromatography was used as a final
purification step and served to exchange the detergent to
lauryl dimethyl amine oxide (LDAO, Anatrace) using a buffer
containing 50 mM Tris-HCl, pH 7.5, 200 mM NaCl, 0.01%
NaN3 and 0.05% LDAO. The protein was concentrated to
20 mg ml1, heptanetriol was added at 3% w/v, and the solu-
tion was mixed with monoolein at a 2/3 protein-to-lipid ratio.
A Mosquito LCP robot (TTP Labtech) was used to dispense
100 nL protein–lipid droplets, overlaid with 750 nL well
solutions. Intimin crystals grew from 100 mM sodium citrate,
pH 4.5–5.5, 50–100 mM NaCl, 100–150 mM MgCl2 and 30–
34% PEG 400. Crystals were mounted directly from the LCP
mixture and flash-cooled in liquid nitrogen.
4. Results and discussion
Data were acquired with both downstream and upstream
versions of the NLO instrument, and schematic representa-
tions along with photographs of the beam paths are shown
in Fig. 1.
Fig. 2 (acquired via the upstream system) shows a large
TsUCH37-UbVME crystal. Both the presence and position of
the crystal can be independently confirmed with bright-field
imaging (a), NLOmicroscopy and XRDmeasurements. Signal
intensities of the corresponding epi-SHG (b), transmission-
SHG (c) and TPE-UVF (d) were measured and processed in
ImageJ. Although the crystal is visible using conventional
optical imaging approaches, NLO microscopy produced
substantial improvements in contrast compared with bright-
field imaging. An X-ray diffraction raster was acquired (e) and
a representative diffraction image is shown ( f).
Intimin protein crystals in LCP were examined using the
upstream NLO system. In Fig. 3 the bright-field image is
shown in (a), with the corresponding trans-SHG image (b),
and X-ray raster acquired with a 5  5 mm beam, confirming
the presence of a protein crystal (c), with the spot having
greatest protein-like diffraction circled and the resulting
diffraction pattern provided (d). All protein crystals identified
by SHG and XRD were accurate for absolute position within
the resolution of the 5 mm X-ray beam.
In Fig. 4 (acquired via the upstream system) a bright-field
image of a kOR-T4L crystal within frozen lipidic cubic phase
is shown (a). As often arises with lipidic mesophase crystal-
lizations, the looped droplets exhibited high optical scattering
upon freezing that frustrated conventional bright-field
imaging approaches for crystal positioning. Transmission SHG
(b) and TPE-UVF (c) images were acquired, exhibiting loca-
lized areas (2–5 mm) of signal within the loop, suggesting the
presence of a crystal. Crystals were confirmed via a 5 mm-
diameter X-ray beam and 5  5 mm cell X-ray raster scan (d),
in which several pixels exhibit weak, but detectable, diffrac-
tion with Bragg analysis consistent with the presence of a
protein crystal. Diffraction patterns for the brightest spot are
shown in Fig. 4(e). However, signal is observed in the trans-
SHG and TPE-UVF images that does not correspond to areas
of protein-like diffraction in the X-ray raster image. This
signal discrepancy is tentatively attributed to protein crystals
that are too small to produce Bragg peaks by XRD, or to the
presence of other ordered materials arising in a false positive.
False negatives for particular focal planes were also observed,
in which analysis of the diffraction patterns obtained from the
raster image indicates the presence of protein-like diffraction
located in areas that did not exhibit substantial SHG or TPE-
UVF due to the finite depth of field (25 mm). However,
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acquisition of multiple focal planes through samples has been
observed to recover crystal locations more quantitatively (not
shown).
In SHG measurements the possibility of false positives
exists from other SHG-active structures. Most notably, some
salts commonly used in crystallization screening can adopt
non-centrosymmetric SHG-active lattices and produce bright
SHG. Alternatively, noncrystalline structures exhibiting
molecular ordering over distances significantly greater than
the wavelength of light can also potentially produce false
positives for SHG. An example of a false positive, from a
noncentrosymmetric vanadate salt crystal, is shown in Fig. S1
of the supplementary information1 in which a cryo-loop
containing a crystal grown in LCP was examined with the
upstream NLO instrument, and yielded substantial signal in
the epi- and transmission-SHG directions. X-ray raster scans
suggested the presence of salt-like diffraction, in addition to
ice diffraction, as there was ice present on the sample loop.
Key signatures for an SHG-active salt were found to be bright
epi-SHG and little to no detectable TPE-UVF. These salt
crystal signatures can be exploited to reduce the likelihood of
false positives. False positives can arise
using TPE-UVF if there is protein
aggregate located within the loop
because TPE-UVF probes the presence
of aromatic residues and is not crystal
specific. Salt crystals and protein
aggregates are common occurrences
with protein crystal growth, generating
false positives for SHG and TPE-UVF
measurements, respectively. Fortu-
nately, most simple salts adopt SHG-
inactive centrosymmetric structures.
Complementary use of these two tech-
niques can significantly reduce the
likelihood of false positives and false
negatives.
Combined NLO imaging and XRD
was also applied to studies of -cellu-
lose, which exhibits fiber-like diffrac-
tion. NLO measurements performed
on loop-mounted cellulose generated
moderate S/N for multiple fibers within
the sample loop (Fig. 5, acquired via
the upstream system). Although fiber
diffraction was evident from the cellu-
lose samples, the DISTL algorithm used
in raster scanning, which searches for
discrete Bragg reflections or spots and
not fiber diffraction, does not indicate
these areas, but rather seems to show
that no measurable sample is present.
Manual inspection of the individual
diffraction patterns was performed to discern the presence of
fiber diffraction.
cPAH crystals ranging in size from 50 mm to 200 mm in
length were imaged with both the downstream instrument
with epi-only detection and X-ray raster scanning [Fig. S2
(supplementary information)]. The locations of intense
protein-like Bragg diffraction typically agreed well with those
of brightest epi-SHG for both large and small cPAH crystals
(e.g. Fig. S2). However, departures between the two were also
observed. Several explanations for the differences were
considered. First, the presence of multiple crystalline domains
within the crystal (e.g. from twinning) may cause the diffrac-
tion spot total to deviate from indicating optimal protein
ordering. Second, inhomogeneous optical scattering of the
incident or detected light can potentially impact the contrast
through effects unrelated to the crystal SHG activity.
However, bright-field images do not suggest substantial
differences in optical transmissivity across the crystal that
might have influenced contrast. Finally, NLO measurements
probe a much narrower depth of field than X-ray diffraction,
which is penetrating. If a particular crystal was not positioned
within the depth of field of the beam-scanning NLO micro-
scope, the SHG efficiency will be substantially reduced or
entirely absent within the detection limits of the instrument.
Despite the quantitative discrepancies, the presence of SHG
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Figure 2
(a) Bright-field image of a T. spiralis UCH37 1-226/UbVME complex crystal (100 mm thick) and
the corresponding (b) epi-SHG, (c) trans-SHG, (d) TPE-UVF and (e) X-ray raster scan within the
300  300 mm box. ( f ) X-ray diffraction of a representative 10 mm-diameter area from (e). X-ray
energy: 12 keV; exposure time: 1 s; photon flux: 2.7  109 photons s1 (10-fold attenuation);
detector distance: 300 mm; maximum theoretical resolution: 2.25 A˚. The large difference in the epi-
and trans-SHG signals is expected for thick samples owing to the difference in the forward and
backward coherence length. The intensities of the two directions will approach equality as the
sample thickness approaches the backwards coherence length (100 nm). Scale bars are 100 mm.
(Three darkened spots, apparent in this figure, arose from separate X-ray ‘burn tests’ to assess X-ray
damage, the results of which will be published in a future study.)
1 Supplementary data for this paper are available from the IUCr electronic
archives (Reference: WA5051). Services for accessing these data are described
at the back of the journal.
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signals above the background correlated with the areas of
the crystal generating a detectable protein-like diffraction,
providing preliminary confirmation of the ability of the
downstream instrument to rapidly generate information for
crystal position as a complement to X-ray raster scanning.
The polyimide loops (MiTeGen) were found to undergo
noticeable deformation with less than 100 mW incident power
using the downstream system, whereas the nylon loops were
more robust, and were not damaged at these powers. No
noticeable damage could be induced in either loop types using
the upstream system during either SHG or TPE-UVF
measurements (120 mW and 90 mW, respectively). Several
mechanisms were considered for the observed laser-induced
damage to the polyimide loops when measured with the
downstream system. Previous studies suggest that damage
from multi-photon absorption and plasma formation was
found to be an important, if not dominant, mechanism for
damage in biological NLO imaging (Sacconi et al., 2006).
However, those measurements were performed under condi-
tions of tight focusing [high numerical aperture (NA)] and
on live cells/tissues. However, alternative mechanisms may
dominate in the present low-NA studies of purified protein
crystals maintained under cryogenic conditions. Local heating
was also considered as a possible damage mechanism, arising
from either one- or two-photon absorption of the incident
beam. The marked difference in damage susceptibilities
between the upstream and downstream systems is consistent
with this mechanism, differing notably in the use of a resonant
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Figure 4
(a) Bright-field image of a membrane protein (human -opioid receptor
complex) crystal in lipidic cubic phase and the corresponding (b) trans-
SHG and (c) TPE-UVF, with (d) an X-ray raster summary overlay
showing corrected Bragg-like reflection counts. (e) X-ray diffraction of
the 5 mm-diameter area corresponding to the red circles in each image.
X-ray energy: 12.0 keV; exposure time: 1 s; photon flux: 2.7 
1010 photons s1 (unattenuated beam); sample-to-detector distance:
300 mm; maximum theoretical resolution: 2.25 A˚. Scale bars are 20 mm.
Cross-hairs were added to (b) and (c) to assist in orienting the fields of
view with respect to the bright-field and diffraction raster images.
Figure 3
(a) Bright-field for an intimin protein crystal generated in LCP with
corresponding (b) trans-SHG and (c) X-ray raster summary overlay
showing corrected Bragg-like reflection counts. (d) X-ray diffraction of
the 5 mm-diameter area corresponding to the red circles in each image,
with X-ray energy 12.0 keV, exposure time 1 s, photon flux 2.7 
1010 photons s1 (unattenuated beam), sample-to-detector distance of
300 mm, resulting in a maximum theoretical resolution of 2.25 A˚. Scale
bars are 50 mm. Cross-hairs were added to (a) and (b) to assist in orienting
the field of view with respect to the diffraction raster images.
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8 kHz scan mirror for the upstream system and a galvan-
ometer-driven mirror operating at 200 Hz on the downstream
system. Rapid beam-scanning using a resonant scanner
combined with long-wavelength (>1 mm) incident light was
shown previously to have no detectable effect on crystal
diffraction quality using a variety of protein crystals, including
myoglobin crystals containing heme groups exhibiting strong
visible light absorption (Kissick et al., 2013). Myoglobin was
specifically chosen, as the color center was anticipated to be
highly susceptible to light-induced perturbation (Banerjee et
al., 1969). However, no statistically significant structural
changes to the lattice were observed in laser-exposed versus
unexposed regions of single crystals (Kissick et al., 2013).
The susceptibility for damage using the polyimide loops
increased notably for TPE-UVF, as the optical transparency
was substantially reduced at 530 nm. Whereas loop absorption
is negligible at 1 mm for SHG, roughly 30% of the incident
530 nm light for TPE-UVF is absorbed by the standard
yellow-tinted polyimide loop material (MiTeGen, http://www.
mitegen.com/). By positioning the loop to avoid the outer
turning points of the fast-scan mirror or blocking the beam at
those locations, no noticeable damage could be induced in the
polyimide loops during TPE-UVF imaging.
Both of the NLO imaging systems presented in this paper
have strengths and limitations, and either could be utilized as
a method for locating and centering protein crystals on a
synchrotron beamline. With a small footprint and the ability to
insert and remove the instrument, there is potential for a
single design of the downstream instrument to be utilized on a
variety of different beamlines. However, the time required for
translating the entire microscope to and from the sample
increases the total time for collecting SHG images and XRD
of the protein. Indeed, the microscope positioning required
substantially more time (2 min) than the sample imaging
(40 s). Furthermore, the absolute accuracy of the translation
stage (in this case,2 mm) can ultimately dictate the precision
in crystal positioning. In addition, the downstream instrument
did not have transmission-SHG detection capabilities. For
protein crystals, detection in transmission provides substantial
improvements in detection limits for weakly SHG-active
proteins, as thickness greater than the crystals’ coherence
lengths can decrease the overall SHG intensity in the epi
direction (Boyd, 2009; Kestur et al., 2012). The absence of
transmission detection could potentially be remedied by
introducing additional optics or integrating into existing
optical paths.
The direct integration of the upstream system eliminated
the need for a translation stage for inserting the microscope,
as was used with the downstream system. This significantly
reduced the time between imaging and XRD, which allowed
for a marked improvement on throughput of data collection.
The upstream system did still require the transmission detec-
tion optics to translate in and out for XRD collection in
transmission, but epi-detected SHG can be performed
concurrently with X-ray diffraction, with only a factor of three
reduction in signal intensity with the mini-beam collimator
in place. The positioning of the collection optics does not,
however, require precise realignment allowing for a significant
improvement on the translation time, as compared with the
downstream instrument, where the entire microscope requires
translation with high precision. The upstream system had
some design trade-offs to accommodate the existing optical
path, which in part accounted for the lower infrared (IR)
throughput and available power in the upstream system. The
biggest losses came from the incident objective in which 80%
of the IR power was lost from reflections because it was not
designed for IR incident light. Choosing optics with a more
broadband anti-reflective coating (ARC) will significantly
improve the power throughput. Testing performed in-house,
with an IR-ARC objective, resulted in a doubling of the
IR transmittance, corresponding to an anticipated four-fold
improvement in signal at the sample (unpublished). The
multiple imaging modes (SHG and TPE-UVF), as well as both
epi and transmission detection, improves the ability of the
upstream system to detect protein crystals that could other-
wise be missed on the downstream system.
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Figure 5
(a) Bright-field image of -cellulose fibers and the corresponding (b) epi-
SHG and (c) trans-SHG images, all 300 300 mm. (d) X-ray diffraction of
a 10 mm-diameter area within the red circle of each image. X-ray energy:
12.0 keV; exposure time: 1 s; photon flux: 2.7  1010 photons s1
(unattenuated beam); sample-to-detector distance: 300 mm; maximum
theoretical resolution: 2.25 A˚. Scale bars are 100 mm. Cross-hairs were
added to (b) and (c) to assist in orienting the fields of view with respect to
the bright-field image.
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Based on these combined results, integrating a NLO
microscope with a synchrotron XRD instrument complements
stand-alone X-ray raster scanning for crystal centering in three
key respects. First, it is expected to minimize radiation-
induced sample damage compared with X-ray raster techni-
ques for X-ray labile crystals or small crystals difficult to
quickly detect at low X-ray flux (Kissick et al., 2013). Second,
NLO microscopy significantly increases the spatial resolution
and reduces the total acquisition time for the determination of
crystal location. For a large sample area (150  150 mm)
scanned with a small beam size (5  5 mm), X-ray raster
images for the protein crystals typically required approxi-
mately 30 min to acquire with a 1 s X-ray exposure time. For
NLO measurements on identical samples, the acquisition time
for the collection of each image was typically <10 s. The
downstream NLO system allows 512  512 pixel images with
40 s acquisitions, and the upstream system allows 150  150
pixel images with 1 s acquisitions, which is roughly a >104-fold
reduction in the per-pixel acquisition time compared with the
X-ray raster acquisition time per cell (3 s per pixel, corre-
sponding to a 1 s exposure, with 2 s of dead-time between
pixel acquisitions). The theoretical resolution of the objective
was 1.6 mm with 2 mm measured spatial resolution. The
downstream NLO system required a total time of 2.5 min for
translation of the microscope from its resting position to the
sample and then back to the resting position following NLO
measurements, resulting in a total acquisition time for each
sample of the order of 3 min, which is still significantly faster
and of higher resolution compared with X-ray raster scan
measurements performed on the same sample. In the
upstream system, no dead-time was required for epi-detection
(in fact, SHG imaging can be performed while acquiring
diffraction measurements), and only a few seconds of trans-
lation time were required to raise and lower the collection
optics in transmission. Third, for weakly diffracting systems
where rapid automated diffraction scoring is challenging,
NLO measurements may significantly increase the ability to
locate protein crystals.
5. Conclusion
Two different designs of integrated NLO instruments were
constructed and characterized targeting applications for
automated sample positioning. The systems were evaluated
using protein crystals (TsUCH37-UbVME, kOR-T4L, cPAH,
Intimin) and fibers (-cellulose). Both NLO and XRD
exhibited good agreement for crystal positioning, consistent
with previous off-line measurements specifically targeting
protein crystals (Kissick et al., 2013). The integrated NLO and
synchrotron XRD instrument was found to enable precise
centering of -cellulose samples for fiber diffraction without
requiring the development of an application-specific analysis
algorithm. The NLO instrument produced images with <10 s
image acquisition times, compared with 3–60 min for X-ray
rastering performed at much lower spatial resolution. By
nature of the higher resolution of NLO image acquisition, the
per-pixel raw data acquisition time was approximately five
orders of magnitude faster than X-ray raster scanning. Once
fully developed, NLO imaging may serve to identify regions of
interest for targeted X-ray scanning, or ultimately serve as the
sole or primary method for precise automated crystal posi-
tioning, such that all of the X-rays striking the crystal are
dedicated to structure elucidation.
Despite these successes, a relatively small variety of crystals
were used to characterize the instruments in this initial study.
Further studies on a greater diversity of protein crystals will
help define the scope of use for NLO methods in automated
centering. Additionally, the present study focused exclusively
on the hardware for visualization, and not on subsequent
algorithms for image analysis and automated crystal posi-
tioning. Higher contrast afforded by NLO imaging has the
potential to significantly improve the reliability of such algo-
rithms if the combined techniques of SHG and TPE-UVF
provide sufficient protein crystal coverage for general-purpose
use.
These studies provided a foundation for future efforts
combining NLO measurements with synchrotron X-ray
diffraction. The data presented here support the use of the
NLO microscopy for automated or manual crystal centering
prior to or in lieu of raster scanning. Potential scope of use
where all optical crystal positioning would be preferred
includes the analysis of smaller crystals (<5 mm), where the
low crystal volume may present challenges for rapid crystal
positioning by X-ray raster scanning. SHG also enables posi-
tioning of fibrous material exhibiting fiber diffraction, such as
cellulose, collagen, chitin etc. Further potential applications
include defect studies, X-ray damage studies and studies of
active pharmaceutical ingredients.
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